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SUMMARY
Cyclosporin is a relatively new immunosuppressant 
drug which has been shown to be useful in prevention of 
graft rejection following organ transplantation. Its 
major disadvantage is its toxicity, which appears to be 
related to high concentrations of the drug. Low 
concentrations are associated with rejection episodes. 
The aim of cyclosporin dosing is to achieve cyclosporin 
concentrations which minimise both toxicity and 
rejection. Individualisation of therapy is necessary 
since cyclosporin has a narrow 'therapeutic range' and 
also exhibits wide pharmacokinetic variability. The . 
aims of this work are to quantify the pharmacokinetic 
variability of cyclosporin in renal and liver transplant 
patients in an attempt to improve control of therapy.
A review of the literature relating to cyclosporin 
outlines the background to the use of the drug and also 
discusses reasons for the pharmacokinetic variability. 
The analytical technique used to measure cyclosporin 
concentrations in whole blood (high performance liquid 
chromatography) is described in detail and validation 
for the method is provided. Pharmacokinetic and 
statistical methods utilised are described.
In an initial study, the pharmacokinetics of 
cyclosporin were investigated in eleven renal transplant 
recipients. A Bayesian technique was used to estimate 
the pharmacokinetic parameters of both a one and a two 
compartment model. This enabled pharmacokinetic 
parameters to be continually revised for each patient
13
over a period of two months following transplantation. 
Revised parameters were used to predict future 
concentrations for which prediction errors were 
calculated. Both models were found to consistently 
under predict later cyclosporin concentrations. 
Examination of the pharmacokinetic parameter estimates 
(of the two compartment model since this was considered 
more appropriate for cyclosporin) showed a decline in
both Cl/F and V q/F. This decline appeared to be
exponential over time post-transplant and three mono­
exponential models were subsequently investigated.
Possible reasons for the change in pharmacokinetics 
were investigated by relating Cl/F to various other 
factors such as biochemical and haematological 
measurements, or demographic data. Although several of 
these factors appeared to explain the change in Cl/F, it 
was not possible to determine whether this was a
causative effect or merely an association. Several of
the factors studied showed upward or downward trends 
which may also be related to time after transplantation, 
and their relationship with time may therefore be 
spurious. The data available suggested that time post­
transplant was the most powerful explanatory variable 
for the change in Cl/F. Inclusion of further factors in 
a monoexponential model containing time may improve 
the model.
The one and two compartment versions of the
Bayesian program used earlier were modified to take into 
account the change in Cl/F. Thus, four models were 
available; one compartment with constant Cl/F, one 
compartment with changing Cl/F, two compartment with 
constant Cl/F and two compartment with changing Cl/F.
The ability of these four models to predict cyclosporin 
concentrations was evaluated in eighteen renal 
transplant patients. The evaluation study was based on 
the prospective collection of data. Results of this 
study showed a significant improvement in accuracy of 
prediction when the modified program (either one or two 
compartment) was used. Precision was poor in all four 
models and possible reasons for this are discussed.
A further study was carried out in 11 liver 
transplant patients. The aim of this study was to 
investigate changes in cyclosporin pharmacokinetics 
following clamping of the external biliary T-tube. A 
series of blood samples was collected from each patient 
following oral and intravenous dosing before and after 
clamping of the T-tube. Of particular interest was a 
possible increase in bioavailability related to 
increased bile flow to the gut following clamping. 
Analysis of data from the eleven patients in the study 
showed an increase in bioavailability which was not 
significant. Two patients with vanishing bile duct 
syndrome at the time of the clamped study may have 
complicated the analysis; omission of these two patients 
resulted in a significant increase in bioavailability at
15
the time of the clamped study. Whether this increase 
was due solely to the effect of T-tube clamping, or 
whether a time dependent factor (as seen in renal 
transplant patients) was involved, was not clear.
These studies have enabled quantitation of some of 
the pharmacokinetic variability of cyclosporin occurring 
in the early period following either renal or liver 
transplantation. The findings presented in this thesis 
should lead to better control of cyclosporin therapy in 
such patients.
16
CHAPTER 1
GENERAL INTRODUCTION AND BACKGROUND
1.1 INTRODUCTION
Cyclosporin is an immunosuppressant drug which has 
played a major role in the survival rate of patients 
with transplanted organs. It was first used clinically 
in renal transplant patients in 1978 (Caine et al, 1978) 
and since then it has been administered to various 
groups of transplant patients, including liver (Starzl 
et al, 1985), cardiac (Oyer et al, 1983) and pancreatic 
transplant patients (Dubernard et al, 1988). Its use 
has also been investigated in prevention of graft versus 
host disease in bone marrow transplant recipients (Storb 
et al, 1985) and it may be of benefit in the treatment 
of auto-immune disease (Dipalma, 1989).
Immunological mechanisms are responsible for graft 
rejection and some means of modifying the immune 
response is therefore necessary (Monaco, 1986). Before 
the introduction of cyclosporin, transplant patients 
were usually treated with corticosteroids and/or 
azathioprine, an approach known as "conventional 
immunosuppression". The introduction of cyclosporin has 
however, significantly improved the success rate of 
renal transplantation (European Multicentre Trial Group, 
1983) and liver transplantation is now considered the 
treatment of choice for nearly all causes of liver 
failure (Gordon et al, 1986).
Cyclosporin, however exhibits several toxic side 
effects, most notably nephrotoxicity. Efficacy and
17
toxicity of cyclosporin are not necessarily related to 
the dose administered, but concentrations of the drug in 
blood or plasma provide a useful method of minimising 
both toxicity and graft rejection (Irschik et al, 1984). 
The blood or plasma concentrations above which 
cyclosporin is effective and below which toxicity is 
unlikely constitute the therapeutic range. This range 
depends on the analytical technique used to measure 
cyclosporin and on the matrix in which it is measured. 
This is discussed later in Chapter 1.
Cyclosporin exhibits inter- and intra-patient 
pharmacokinetic variability resulting in unpredictable 
concentrations (Newburger and Kahan, 1983). The 
combination of a relatively narrow therapeutic range and 
wide pharmacokinetic variability has necessitated 
frequent monitoring of cyclosporin concentrations.
A method of individualising cyclosporin dosage 
based on pharmacokinetic principles using measured 
concentrations would be of great benefit. Single dose 
pharmacokinetic profiles performed either pre- or post- 
operatively (Lokiec et al, 1986; Kahan et al, 1986c) 
take account of differences between individuals but 
cannot account for important differences which occur 
within individuals. This latter problem is addressed by 
Bayesian estimation of pharmacokinetic parameters 
(Sheiner and Beal, 1982; Kelman et al, 1982), a 
technique which requires only one or two concentration 
measurements in each dosing interval and which may be
18
employed to continually revise pharmacokinetics in 
individual patients over a period of several weeks. 
Bayesian estimation is described more fully in Chapter 
3.
This thesis involves the study of pharmacokinetic 
variability in renal and in liver transplant recipients, 
both within and between patients. This chapter provides 
a background of the immunological mechanisms involved in 
destruction of organ transplants and presents the need 
for immunosuppressant drugs. The advantages and 
disadvantages of cyclosporin will be discussed in 
relation to conventional therapy. Cyclosporin 
pharmacokinetics will be discussed in detail and the 
aims of the thesis will be outlined.
1.1.1 Immunological Response to Organ Grafting
A transplant between two genetically identical 
twins (isograft) does not evoke an immune response 
(Merrill et al, 1956). However, isografts are uncommon 
and allografts (same species but different genetic 
constitution) are much more usual. If no attempt is 
made to modify the immune system of the allograft 
recipient, rejection of the transplant will occur after 
a short period of time. An immune response directed 
against the cells of an allograft occurs because the 
antigens of the graft are genetically different from 
those of the recipient.
19
Antigenic expression on the cell surface of an 
allograft is genetically controlled by the major 
histocompatibility complex (MHC) and, in particular the 
human leukocyte antigen (HLA). Attempts are usually 
made to match the donor and recipient at the MHC, but 
even where they are well matched, rejection can still 
occur (Pfeffer et al, 1988).
Acute allograft rejection is mainly due to cellular 
immunity, that is immunity involving T-cells without the 
formation of free antibodies. The second main type of 
immune response, humoral immunity involving B-cell 
lymphocytes, is thought to play a smaller part in acute 
rejection. The rejection process involves a complex 
sequence of events. Antigens on the allograft are 
recognised as foreign and trigger the proliferation of 
activated T-cells from the lymphatic tissue. This leads 
to the release of cytotoxic T-cells whose function is to 
damage the cells of the allograft, helper T-cells which 
allow T-dependent B-cells to respond to certain 
antigens, and suppressor T-cells which result in 
feedback suppression of the immune response. The 
transplanted organ is destroyed by injury to blood 
vessels, resulting in ischaemia and necrosis.
1.1.2 Immunosuppressant Drugs
Transplant survival depends upon suppression of the 
immune system and, following transplantation, virtually
20
all patients receive immunosuppressant drugs. Ideally, 
the immunosuppressant agent should protect the cells of 
the allograft while having a minimal effect on the 
recipient, that is, it should inhibit only the T-cells 
known to be involved in the rejection process. The 
following section describes immunosuppressant drugs 
commonly used.
(i) Azathioprine
Azathioprine has now been used for about 30 years. 
It is a nitro-imidazole derivative of 6-mercaptopurine 
which is its active component. Six-mercaptopurine is 
liberated by metabolic cleavage in the liver after 
absorption (Figure l.l). It is thought to inhibit T- 
cell proliferation (Hall, 1982) by interfering with 
nucleic acid synthesis. Azathioprine therapy however, 
increases the incidence of infections in the recipient 
and also has a toxic effect on the bone marrow. Before 
the introduction of cyclosporin, azathioprine in 
combination with corticosteroids was the most common 
means of suppressing the immune system following organ 
transplantation and is termed "conventional therapy".
(ii) Corticosteroids
Corticosteroids are used in virtually all 
transplant patients either in combination with 
azathioprine or, more recently, with cyclosporin. The 
chemical structures of the corticosteroids, prednisone
21
Figure 1.1 Chemical structure of azathioprine
CH.
Cleaved at this point 
to release 6-mercaptopurine
H
Figure 1.2 Chemical structure of prednisone and 
prenisolone
ch2 oh
•0
OH
Prednisone
R — OH Prenisolone
and its active moiety prednisolone, are shown in Figure 
1.2. The corticosteroids act by binding to the DNA 
molecule, followed by increased transcription of mRNA 
molecules. This leads to alterations in protein 
synthesis and changes in cell function (MUkwaya, 1988), 
thus suppressing proliferation and differentiation of T- 
cells. Steroids can cause several unwanted side effects 
including growth retardation in children, Cushingoid 
features, obesity, hypertension and infection. 
Fortunately, lower doses of steroids can be used when 
the drug is used in combination with cyclosporin and 
some steroid side effects can be avoided.
(iii) Cyclophosphamide
Cyclophosphamide was used in the early years of 
transplantation but is less commonly used nowadays. It 
is inactive in vitro and is transformed in the liver 
into active metabolites. The active metabolites 
interfere with replication of immunologically competent 
cells by crosslinking to DNA (Yadav et al, 1988).
(iv) Total lymphoid irradiation
Total lymphoid irradiation is a means of 
immunosuppression limited to the lymphoid system. In 
animals, it has been shown to produce involution of the 
lymphoid system followed by preferential regeneration of 
T-suppressor cells (Slavin et al, 1978).
22
(v) Orthoclone 0KT3
This is a murine monoclonal antibody which acts by 
inhibition of cytotoxic T-cells (Hirsch et al, 1987).
It is used in some centres instead of steroids to 
reverse acute rejection episodes.
(vi) Antilymphocyte and antithymocyte globulin (ALG and 
ATG)
ALG and ATG exert a non-specific action against 
the lymphocytes and are useful in treating sensitised 
patients, for example those who have had a previous 
transplant.
(vii) FK 506
FK 506 is a new drug, produced as part of a drug 
program which was designed to identify fungal 
metabolites that would inhibit interleukin 2 (IL-2) 
production (Morris et al, 1989). Preliminary studies 
suggest that it is useful both as "salvage therapy" in 
patients with rejection or nephrotoxicity after 
receiving other immunosuppressant drugs, and as primary 
immunosuppression in high risk patients (Starzl et al, 
1989).
(viii) Cyclosporin
The introduction of cyclosporin as a new class of 
immunosuppressant drug has played a major role in 
improving the success rate of kidney, liver, heart,
23
heart-lung, bone marrow and pancreas transplantation 
(Beveridge, 1986). Its chemical structure differs 
markedly from that of earlier immunosuppressant drugs 
(Figure 1.3). The potent immunosuppressive properties 
of cyclosporin were reported in 1976 (Borel et al, 1976) 
and the first clinical trial was carried out in seven 
renal transplant patients in 1978 (Caine et al, 1978). 
Cyclosporin was found to differ from earlier 
immunosuppressant drugs in its selective action on T- 
lymphocytes (Borel et al, 1977). The following section 
will outline the mechanism of action of cyclosporin.
1.2 CYCLOSPORIN
1.2.1 Background
Cyclosporin was fortuitously isolated from a soil 
fungal culture during a microbiological screening 
programme (Dreyfuss et al, 1976). Although it was 
found to have little anti-fungal activity, it showed 
potent immunosuppressant properties in animals (Borel et 
al, 1976). Cyclosporin is a cyclic undecapeptide of 
molecular weight 1202. Ten of the amino acids were 
already known but the C-9 amino acid on position 1 is 
unique and appears to be essential for immunosuppression 
although it is not active on its own (Wenger, 1986) .
1.2.2 Mechanism of Action
Cyclosporin has a selective action on T-lymphocytes
24
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(Borel et al, 1977) and appears to inhibit the release 
of IL-2 by stimulated helper T-cells (Hess et al 1983). 
The site of action of cyclosporin is shown in Figure 
1.4. Cyclosporin has a sparing effect on suppressor T- 
cells; there is thus a change in the ratio of 
suppressor:effector cells (Kupiec-Weglinski, 1984).
At the cellular level it appears that inhibition of 
IL-2 production by activated helper T-lymphocytes occurs 
at the level of messenger ribonucleic acid (mRNA) 
transcription (Elliott et al, 1984); it may be that 
cyclosporin inhibits calmodulin dependent inducible mRNA 
transcription (Hess and Colombani, 1986).
Cyclosporin does not inhibit cytotoxic T-cells 
which are already formed? the drug is therefore 
ineffective if treatment is started after antigenic 
stimulation has occurred (Wish, 1986).
Cyclosporin is thought to have no effect on humoral 
immunity (Borel et al, 1977) although there is some 
conflicting evidence on this (Paavonen and Hayry,1980).
1.2.3 Adverse Effects of Cyclosporin
Cyclosporin exhibits several toxic side effects, 
the most serious of which is nephrotoxicity. 
Nephrotoxicity occurs both in transplant patients (Caine 
et al, 1978) and in patients receiving the drug for 
other reasons (Dijkmans et al, 1987; Tegzess et al,
1988). The most likely site of action of cyclosporin on
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Figure 1.4 Diagram of the immune response to organ 
transplantation and site of action of 
cyclosporin
Site of action of cyclosporin
precursor
cytotoxic
T-cell
Cytotoxic ^  
T-Lymphocyte
laturation
precursor
suppressor
T-celt
maturation
Cytotoxic 
T-lymphocytes
Suppressor
T-cells
From: Hess et al, 1983.
the nephron is the afferent arteriole where it produces 
vasoconstriction (Kahan, 1989). Nephrotoxicity is 
characterised by a decrease in fluid output from the 
proximal tubules, an increase in proximal fractional 
reabsorption and a moderate decrease in the glomerular 
filtration rate, probably caused by a reduction in renal 
blood flow (Dieperink et al, 1987). Animal studies 
suggest that the renin-angiotensin aldosterone system is 
involved (McAuley et al, 1987).
Nephrotoxicity is usually heralded by an increase 
in serum creatinine. However in the case of renal 
transplantation, it is difficult to determine whether an 
increased serum creatinine is due to nephrotoxicity or 
to rejection of the transplanted organ. Nephrotoxicity 
is thought to be associated with high cyclosporin 
concentrations and rejection with low concentrations 
(Irschik et al, 1984). An increase in creatinine due to 
rejection caused by inadequate cyclosporin levels will 
generally be reversed by treating with high dose 
steroids whereas increased creatinine due to 
nephrotoxicity is not reversed in this way (Taube et al,
1985). The use of ultrasound to detect an increase in 
cross-sectional area of the kidney (Parvin et al, 1986) 
or graft biopsy (Thomsen et al, 1987) may help to 
differentiate between the two conditions. Clinical 
signs indicating rejection include decreased urine 
output, increased weight, an increase in body
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temperature and a rapid increase in serum creatinine. 
Nephrotoxicity is usually associated with a slower 
increase in serum creatinine (Klintmalm et al, 1983). 
Hepatotoxicity occurs in many patients but usually 
reverses on dosage reduction (Lorber et al, 1987). 
Hypertension is also common although the relationship 
with cyclosporin concentration is less clear (Loughran 
et al, 1985). Increased plasma LDL concentrations 
following renal transplantation may be associated with 
cyclosporin therapy (Raine et al, 1987). Seizures as a 
result of neurotoxicity may be related to elevated 
cyclosporin concentrations (Beaman et al, 1985). The 
incidence of lymphoma associated with cyclosporin is 
less frequent than that found with conventional 
immunosuppression; lymphomas which do occur generally 
respond to reduction in dose or termination of 
cyclosporin therapy (Starzl et al, 1984).
1.3 PHARMACOKINETICS OF CYCLOSPORIN
1.3.1 Absorption
Cyclosporin is a highly lipophilic compound which 
can be given orally in an oily suspension or in soft 
gelatin capsules. Its absorption is slow, variable and 
incomplete. The time to peak concentration following an 
oral dose varies between 1 and 8 hours (Ptachcinski et 
al, 1985b). Bioavailability of orally administered 
cyclosporin is variable. Values ranging from 5% to 60%
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are reported (Ptacheinski et al, 1986). To make the 
oily solution more palatable it is usually mixed with 
fruit juice or milk. Oral absorption of the drug is 
unlikely to be affected by the vehicle (Johnston et al, 
1986), although others have observed higher peak 
concentrations and higher area under the concentration 
time curve (AUC) when cyclosporin is mixed with milk 
rather than orange juice (Keogh et al, 1988).
The mechanism of absorption of cyclosporin is 
unclear. In animal studies, despite its lipophilicity, 
only about 2% of the drug is absorbed by the lymphatic 
system (Ueda et al, 1983). It is likely that 
cyclosporin is absorbed in the small intestine with 
micelles formed from bile (Lindholm et al, 1988c). Bile 
is necessary for absorption of cyclosporin in dogs 
(Ericzon et al, 1987) and animal studies show that poor 
absorption occurs in hepatic dysfunction, presumably due 
to lack of bile (Takaya et al, 1987). In liver 
transplant patients, very low concentrations of 
cyclosporin are detected after an oral dose during 
periods of biliary diversion; AUC increases following 
clamping of the external bile drain (Mehta et al, 1988) 
probably due to increased absorption (Andrews et al,
1985). Similarly in animal studies, the presence of 
bile results in approximately three fold increase in 
bioavailability of cyclosporin in dogs, compared to 
those with biliary diversion (Venkataramanan et al,
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1986b). The concomitant administration of bile salts 
and cyclosporin to liver transplant patients may 
overcome this problem (Ericzon et al, 1987).
Pharmacokinetic studies of cyclosporin are usually 
carried out assuming first order absorption ie assuming 
that the rate of absorption is proportional to the 
concentration of drug in the gut (Newburger and Kahan, 
1983). Zero order absorption (which assumes a constant 
rate of absorption independent of the concentration in 
the gut) and the presence of an "absorption window" in 
the gut has been proposed (Grevel et al, 1986). The 
absorption of cyclosporin may be dose dependent, ie at 
lower doses relatively more of the drug is absorbed 
(Grevel,.1988; Reymond et al, 1988). Conversely, Ueda 
et al (1984) have reported that in animal studies the 
proportion of cyclosporin absorbed increases as dose 
increases.
The effect of food on the absorption of cyclosporin 
is controversial. Food is reported to reduce 
bioavailability (Keown et al, 1982), to have no effect 
(Keown et al, 1983; Keogh et al, 1988) and to increase 
bioavailability (Ptachcinski et al, 1985c; Gupta and 
Benet, .1989) . The .presence of intestinal dysfunction, 
such as vomiting or diarrhoea, impairs absorption 
(Atkinson et al, 1984).
As a result of the various factors discussed above, 
there is considerable variability between subjects in 
cyclosporin absorption and bioavailability. In the
29
first two weeks following renal transplantation a mean 
(SD) bioavailability of 27.6% (18.1) has been repprted, 
and in 7 of 41 subjects bioavailability was less than 
10% (Ptachcinski et al, 1985b). In liver transplant 
recipients, bioavailability values ranging from 8% to 
60% (mean 27%) have been reported (Burckart et al,
1986c).
Of crucial importance is the finding that 
bioavailability also varies considerably within subjects 
both in healthy volunteers (Lindholm et al, 1988c) and 
in renal transplant recipients (Kahan et al, 1983?
Odlind et al, 1986). In the case of renal 
transplantation, it is known that as time progresses 
post transplant, the dose of cyclosporin must be reduced 
in order to maintain constant steady state 
concentrations (Tufveson et al, 1986). Bioavailability 
has been reported to increase gradually in the early 
period following renal transplantation (Kahan et al, 
1983; Odlind et al, 1986). This has been verified by 
the finding that the same dose of cyclosporin given at 
about 3 days and again at about 7 months after a renal 
transplant results in a greater amount absorbed at the 
later time (Wilms et al, 1988). Similarly a mean 
bioavailability of 25.9% (19.4) in the first two weeks 
post transplant rising to 50.2% (7.9) at 6-12 months has 
been reported by Kahan et al (1986a).
Various theories for an increase in bioavailability
30
have been proposed. One possibility is that it is a 
time dependent change as the patient recovers post 
operatively (Venkataramanan et al, 1989). As previously 
discussed, bile is necessary for absorption of orally 
administered cyclosporin and poor bile flow immediately 
post-operatively may lead to impaired absorption. In 
addition, patients with renal failure often have altered 
gastric pH or gastro-intestinal dysfunction, both of 
which may impair drug absorption (Venkataramanan et al, 
1989) immediately after transplantation.
1.3.2 Distribution
Cyclosporin exhibits multicompartmental behaviour 
following intravenous administration (Ptachcinski et al, 
1987a; Follath et al, 1983). An initial rapid, 
distribution phase, with a half life of about 0.1 hours 
is followed by a second slower distribution phase with a 
half life of the order of 1 hour and a terminal phase 
with an elimination half life of about 16 hours (Follath 
et al, 1983) .
Cyclosporin distributes widely in the body as a 
result of its lipophilicity. Some reported values for 
volume of distribution are shown in Table 1.1. High 
concentrations of the drug have been detected in adipose 
tissue, liver, intestine, gall bladder, pancreas, 
kidney, adrenal glands, spleen and lymph nodes (Ried et 
al, 1983). A recent study has shown similar disposition 
of cyclosporin in lean and obese patients, suggesting
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Table 1.1 Reported pharmacokinetic parameter values 
for cyclosporin in different groups of patients (measured 
in whole blood by HPLC).
Patient
group
Clearance
(1/h/kg)
Volume of 
distn 
d/kg)
Elirn11 
half life 
(hours)
Ref
Healthy
volunteers
0.234
(0.174-0.330)
1.3
(0.3)
6.2
(4.2-12.6)
(i)
Renal
transplant
0.342
(0.038-1.43)
4.54
(3.59)
10.7
(4.5-53.4)
(ii)
Liver
transplant
0.308
(0.192-0.456)
- - (iii)
Cardiac
transplant
0.390
(0.126-0.906)
2.7
(2.0)
6.4 (iv)
Clearance; harmonic mean (range)
Volume of distribution; arithmetic mean (standard
deviation)
Elimination half life; harmonic mean (range)
References: (i) Ptachcinski et al, 1987a,
(ii) Ptachcinski et al, 1985b,
(iii) Burckart et al, 1986a,
(iv) Venkataramanan et al, 1985
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that the drug is distributed primarily in lean body mass 
(Yee et al, 1988a). Permeability of the blood/brain 
barrier is poor (Cefalu and Partridge, 1985) which 
conflicts with reports of central nervous system 
toxicity (Beaman et al, 1985). The drug is also 
distributed into breast milk (Flechner et al, 1985).
The distribution of cyclosporin in blood is both 
temperature and cpncentration dependent. At 37°C 
approximately 58% of cyclosporin is associated with 
erythrocytes (Lemaire and Tillement, 1982) . At lower 
temperatures in vitro, cyclosporin partitions 
increasingly into blood cells (Niederberger et al,
1983). The effect of this on the measurement of 
cyclosporin concentrations is discussed more fully in 
Chapter 2. Erythrocytes become saturated at 
concentrations greater that 5000ug/l. There is, 
however, little evidence for a relationship between 
haematocrit and the volume of distribution of 
cyclosporin (Yee et al, 1988c).
Cyclosporin is also highly bound to plasma 
proteins, particularly the lipoproteins (Lemaire and 
Tillement, 1982). Any change in lipoprotein 
concentration may affect binding and thus result in 
altered disposition of cyclosporin (Lithell et al, x
1986). It is possible that some of the variability in 
pharmacokinetics of cyclosporin can be explained by 
alterations in clinical parameters that reflect binding 
of cyclosporin in the blood (Kasiske et al, 1988). One
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group has observed increased haematocrit, LDL, HDL, 
total cholesterol, triglycerides, total protein and 
albumin post transplant and suggests that the observed 
changes in pharmacokinetics of cyclosporin are due to 
changes in binding of the drug (Awni et al, 1989).
1.3.3 Metabolism
Cyclosporin is extensively metabolised in the liver 
(Maurer, 1985). Nine metabolites have been identified 
although at least 25 are thought to exist 
(Venkataramanan et al, 1989). Biotransformation is 
limited to N-demethylation, hydroxylation and 
cyclization.
The metabolites may contribute to the 
immunosuppressant or toxic effects of cyclosporin. Some 
metabolites do have immunosuppressive activity (Rosano 
et al, 1987) and concentrations of cyclosporin measured 
by a non-specific radio-immunoassay (measures both 
parent drug and some of its metabolites) have been 
reported to correlate better with nephrotoxicity than 
those measured by high performance liquid chromatography 
which detects parent drug only (Holt et al, 1986; Yee et 
al, 1986). This suggests involvement of some of the 
detected metabolites.
Cyclosporin is primarily metabolised by the 
cytochrome P-450 system in the liver and consequently 
any concomitant drug therapy which induces or inhibits
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this system may affect drug concentrations (Section 
1.5 ,, ) . Patients with liver dysfunction metabolise 
cyclosporin more slowly than other groups of patients 
(Kahan et al, 1986a, Takaya et al, 1988).
1.3.4 Elimination
Cyclosporin metabolites are primarily eliminated 
via the bile. Less than 2% of an absorbed dose is 
excreted unchanged by this route (Burckart et al 1986b). 
Approximately 6% of administered cyclosporin is excreted 
in the urine, and less than 1% is excreted unchanged in 
the urine (Wood et al, 1983). Enterohepatic 
recirculation of parent drug does not occur, although 
some metabolites are recirculated (Venkataramanan et al, 
1985b). Some reported values of clearance of 
cyclosporin in various groups of patients are shown in 
Table 1.1.
Elimination of cyclosporin follows first order 
pharmacokinetic behaviour, although during rapid 
intravenous infusion (>6mg/kg/hour), elimination may 
become zero order (Kahan, 1985a). Gupta et al, (1987) 
have shown a lower clearance at higher doses, but this 
is unlikely to be of clinical significance.
Cyclosporin is almost completely metabolised in the 
liver and consequently a deterioration in liver 
function, as defined by increased bilirubin or 
transaminase levels, may result in decreased clearance 
(Kahan et al, 1986a). A non-linear relationship has
been reported between alanine amino transferase (ALAT), 
which is indicative of hepatocyte damage, and 
cyclosporin clearance in uraemic patients (Reynolds et 
al, 1988). The relationship between bilirubin levels 
and cyclosporin disposition is more difficult to 
interpret since bilirubin levels may well be an index of 
liver function and therefore of cyclosporin metabolism, 
but may also be a measure of bile flow into the gut, an 
important consideration in the absorption of 
cyclosporin. In animal studies a significant negative 
correlation has been reported between serum bilirubin and 
bioavailability (Takaya et al, 1988) but the same group 
was unable to show a relationship between bilirubin 
levels and the clearance of intravenously administered 
cyclosporin. A study in bone marrow transplant patients 
showed no correlation between liver function tests and 
cyclosporin clearance (Yee et al, 1988b).
Renal function does not affect cyclosporin 
clearance (Follath et al, 1983; Roberts et al, 1986). 
Reports of a relationship between renal function and 
cyclosporin clearance are based on results obtained 
using a non-specific radio-immunoassay (see Chapter 2) 
(Arnold et al, 1987; Kahan et al, 1986a). However the 
effect of renal function on cyclosporin disposition is 
difficult to interpret and it is possible that some 
factor relating to improved renal function following a 
successful transplant may cause changing
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pharmacokinetics of the drug. The clearance of 
cyclosporin is not affected by haemodialysis.
Hepatic extraction of cyclosporin is low to 
moderate (Venkataramanan et al, 1985a) which indicates 
that its clearance may be altered by changes in 
intrinsic clearance and blood protein binding, and to a 
lesser extent by changes in liver blood flow. As 
indicated earlier, cyclosporin is a lipophilic compound 
and is highly bound to lipoproteins. There is a close 
relationship between lipoprotein levels and cyclosporin 
clearance in uraemic patients awaiting renal 
transplantation (Lithell et al, 1986; Lindberg et al,
1986), possibly due to a reduction in the fraction of 
cyclosporin unbound with increasing cholesterol 
concentration (Legg et al, 1988). The decrease in 
cyclosporin clearance with age (Kahan et al, 1986a) may 
be due to increased lipoprotein concentrations which 
occur in older patients (Yee et al, 1987). Lipid 
abnormalities are common in patients undergoing 
dialysis, and transplantation may not overcome this. A 
significant increase in cholesterol in patients with 
hypercholesterolaemia has been shown one year post­
transplant compared to pre-transplant (Kasiske et al,
1987). This increase may be due to cyclosporin itself 
(Raine et al, 1987) or to both cyclosporin and 
prednisolone (Harris et al, 1986 ; Vathsala et al,
1989) .
Clearance of cyclosporin in bone marrow transplant
37
patients is higher than in other groups of transplant 
patients, possibly due to lower haematocrit levels in 
the former group (Yee et al, 1988b).
The requirement for lower cyclosporin doses as time 
progresses following renal transplantation, may be 
partly due to a decreased elimination with time 
(Newburger and Kahan, 1983; Habucky et al, 1988).
1.4 EFFECT OF DEMOGRAPHIC FACTORS ON THE PHARMACO­
KINETICS OF CYCLOSPORIN
Various demographic factors have been found to 
contribute to the inter-patient pharmacokinetic 
variability of cyclosporin. The effect of hepatic 
impairment, renal dysfunction and gastro-intestinal 
dysfunction have been discussed earlier in this chapter.
Renal transplant patients over 45 years of age have 
lower clearance and higher volume of distribution than 
younger patients (Kahan et al, 1986a); females have 
higher clearance and higher volume of distribution than 
males.
There appears to be no relationship between the 
pharmacokinetics of cyclosporin, and haematocrit, 
haemoglobin, bilirubin, albumin, aspartate transaminase, 
lactate dehydrogenase or alkaline phosphatase (Grevel et 
al, 1988a), although a significant relationship between 
alanine transaminase and clearance has been observed 
(Grevel et al, 1988a). This relationship is seen
38
regardless of whether cyclosporin is measured in whole 
blood by specific high performance liquid chromatography 
or by non-specific radio-immunoassay. A relationship 
between alanine transaminase and bioavailability is 
found only when cyclosporin is measured in serum by non­
specific radioimmunoassay.
1.5 DRUG INTERACTIONS
Drug interactions with cyclosporin are of two 
types: (i) drugs altering the pharmacokinetics of 
cyclosporin or whose pharmacokinetics are altered by 
cyclosporin, and (ii) drugs affecting the toxicity of 
cyclosporin.
(i) Drugs which alter the pharmacokinetics of 
cyclosporin usually do so by interfering with either the 
absorption or the metabolism of the drug. Some 
interactions which have been investigated are discussed 
below and also listed in Table 1.2.
Metoclopramide has been reported to improve 
absorption of cyclosporin by increasing gastric 
emptying, therefore decreasing the time taken for the 
drug to reach small intestine absorption sites.(Wadhwa,
1987).
The calcium channel blockers, diltiazem (Wagner et 
al, 1989), nicardipine (Bourbigot et al, 1986) and 
verapamil (Lindholm and Henricsson, 1987) cause 
increased cyclosporin concentrations. The mechanism of
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Table 1.2 Reported pharmacokinetic drug interactions 
with cyclosporin
Drug Effect on
Cyclosporin
Concentrations
Reference
Metoclopramide Increases Wadhwa, 1987
Erythromycin Increases Ptachcinski et al, 
1985d, Gupta et 
al, 1988.
Diltiazem Increases Wagner et al, 
1989
Nicardipine Increases Bourbigot et al, 
1986.
Verapamil Increases Lindholm and 
Henricsson, 1987.
Nifedipine No effect Bourbigot et al, 
1986.
Steroids Increase
Decrease
Ost et al, 1985. 
Ptachcinski et al, 
1987b
Carbamazepine Decreases Lele, 1985.
Phenobarbitone Decreases Carstensen et al, 
1986.
Phenytoin Decreases Freeman et al, 
1984 ? Rowland 
and Gupta, 1987.
Sodium valproate No effect Hillebrand et al, 
1987.
Rifampicin Decreases Langhoff and 
Madsen, 1983.
Sulphonamides Decreases Jones et al, 1986.
Cimetidine No effect 
Increases
Jarowenko et al, 
1986.
Cockburn, 1986.
Ciprofloxacin No effect Tan et al, 1989.
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this interaction is probably inhibition of hepatic 
microsomal drug metabolism (Renton, 1985). This 
interaction is not seen with nifedipine (Wagner et al, 
1989? Bourbigot et al, 1986). It is of note that 
despite the increase in cyclosporin concentrations 
caused by diltiazem, nicardipine and verapamil, the 
glomerular filtration rate is not decreased (Wagner et 
al, 1989). This suggests that the calcium blocking 
drugs may have a protective effect on renal function 
possibly due to their vasodilator effect (Feehally et 
al, 1987).
Carbamazepine and phenobarbitone cause a decrease 
in cyclosporin concentrations, possibly due to induction 
of the cytochrome P450 enzyme system (Carstensen et al, 
1986; Lele et al, 1985). Concomitant administration of 
phenytoin also causes decreased cyclosporin 
concentrations, but it is not clear whether this is due 
to decreased absorption (Rowland and Gupta, 1987) or to 
increased metabolism (Freeman et al, 1984). No such 
interaction has been reported between cyclosporin and 
sodium valproate (Hillebrand et al, 1987).
The use of high dose methylprednisolone during 
rejection episodes may affect cyclosporin 
pharmacokinetics. Increased cyclosporin concentrations 
have been seen during concomitant administration of both 
drugs when cyclosporin concentrations are measured by 
non-specific radio-immunoassay (Klintmalm and Sawe,
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1984? Ost et al, 1985), presumably due to inhibition of 
cyclosporin metabolism. However, when cyclosporin is 
measured by specific high performance liquid 
chromatography, an increase in cyclosporin clearance is 
seen (Ptachcinski et al, 1987b).
Erythromycin causes increased concentrations of 
cyclosporin (Ptachcinski et al, 1985d) either by 
inhibiting its metabolism (Vereerstraeten et al, 1987) 
or by enhancing its absorption (Gupta et al, 1988).
The interactions with rifampicin and isoniazid 
(Langhoff and Madsen, 1983), sulphonamides (Jones et al, 
1986) and ketoconazole (Ferguson et al, 1982) are 
probably due to alteration in cyclosporin metabolism. 
Ketoconazole inhibits metabolism of cyclosporin and its 
concomitant use may allow lower doses of cyclosporin to 
be used (First et al, 1989).
Spiramycin has no effect on the pharmacokinetics of 
cyclosporin (Guillemain et al, 1989? Birmele et al,
1989) suggesting that spiramycin is metabolised by a 
different isoenzyme than cyclosporin. Similarly, in 
spite of the effects of ciprofloxacin on 
pharmacokinetics of other drugs metabolised by the 
cytochrome P450 enzyme system (Bachmann et al, 1988), 
ciprofloxacin does not appear to affect the 
pharmacokinetics of cyclosporin (Tan et al, 1989).
Other workers have been unable to detect any effect of 
norfloxacin on serum cyclosporin trough concentrations 
(Jadoul et al, 1989).
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Cyclosporin itself affects the pharmacokinetics of 
some drugs. Digoxin toxicity has been observed in heart 
transplant patients treated with cyclosporin due to 
altered pharmacokinetics of digoxin (Dorian et al,
1988). The interaction between cyclosporin and 
prednisolone is mutual as shown by increased 
prednisolone concentrations when the two drugs are 
administered concurrently (Ost et al, 1985).
Cyclosporin itself has been reported to inhibit the 
cytochrome P450 enzyme system (Moochala and Renton,
1986).
(ii) The second group of drug interactions includes 
drugs which are nephrotoxic themselves and may enhance 
the toxicity of cyclosporin. Both gentamicin and 
cyclosporin exert a toxic effect on the renal proximal 
tubule and it has been reported that the total 
nephrotoxicity when these two drugs are given together 
is greater than the sum of their individual toxicity 
when given alone (Whiting and Simpson, 1983). The 
mechanism by which amphotericin B causes nephrotoxicity 
is unclear but it has been reported to enhance the 
toxicity of cyclosporin when given in combination 
(Kennedy et al, 1983). In animal studies, frusemide has 
been seen to cause abnormalities of the renal tubules 
which are more severe when administered at the same time 
as cyclosporin (Whiting et al, 1984b).
Some drug interactions are beneficial and may
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reduce toxicity. Cyclosporin nephrotoxicity appears to 
be caused by vasoconstriction of the renal arterioles 
and it has been reported that vasodilators, in 
particular nifedipine, may have a protective effect on 
renal function (Dieperink et al, 1986; Feehally et al,
1987) .
1.6 MONITORING OF CYCLOSPORIN THERAPY
Pharmacokinetic variability of cyclosporin, coupled 
with the toxicity of the drug, has necessitated regular 
monitoring of cyclosporin concentrations in virtually 
all patients receiving the drug. Until the recent 
introduction of a specific monoclonal antibody for 
radio-immunoassay, most transplant centres used a non­
specific radio-immunoassay because of the speed and ease 
of this type of assay. High performance liquid 
chromatography (HPLC) was the only specific assay 
available. The equipment required by HPLC and the time 
taken to perform the assay limited its use in routine 
clinical laboratories. Analytical methods will be 
discussed in more detail later in this section and in 
Chapter 2.
It is generally accepted that measuring of 
cyclosporin trough concentrations in blood or plasma is 
useful in minimising toxicity and rejection (Irschik et 
al, 1984). Similar findings have been reported by Kahan 
et al (1984). Lower cyclosporin plasma levels in renal
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transplant patients with acute rejection have been 
observed compared to non-rejecting patients (Lindholm et 
al, 1988b). Furthermore, the same group has reported a 
significantly lower free fraction of cyclosporin during 
periods of acute rejection compared to one week earlier 
(Lindholm et al, 1988a). Others have shown that 
monitoring of cyclosporin concentrations is useful in 
prevention of nephrotoxicity in bone marrow transplant 
recipients but does not help to prevent graft-versus- 
host disease (Lindholm et al, 1987). Conversely, 
Rogerson et al (1986) found that measurement of 
cyclosporin concentrations in renal transplant patients 
is helpful in determining minimum concentrations to 
prevent rejection but does not help to prevent 
nephrotoxicity. It may be that both pharmacokinetic and 
pharmacodynamic monitoring are useful in optimising 
cyclosporin therapy (Kahan et al, 1985b).
The measured concentration of cyclosporin is highly 
dependent on the type of assay used (ie specific or non­
specific) and on the matrix in which the drug is 
measured (ie blood, plasma or serum). Radio-immunoassay 
is the most commonly used analytical technique as it is 
relatively simple and fast to perform. However, until 
recently the antibody used in the radioimmunoassay was 
non-specific (ie it measured both parent drug and 
metabolites). HPLC is a specific technique but is too 
time consuming for most routine laboratories. The 
introduction of a specific antibody for cyclosporin
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should combine the ease of radio-immunoassay with the 
specificity of HPLC (see Chapter 2). The matrix of 
analysis is also important due to partitioning of 
cyclosporin between plasma and blood cells. Whole blood 
appears to be the matrix of choice as this overcomes 
methodological problems associated with altered 
haematocrit and changes in temperature during storage of 
the blood sample (Shaw et al, 1987).
Most commonly, trough concentrations are measured 
ie samples are collected immediately before a dose.
Table 1.3 lists some proposed therapeutic ranges for 
cyclosporin concentrations using different analytical 
methods (24 hour trough samples, renal transplant 
patients).
Trough cyclosporin concentrations are usually 
measured because variability in the ratio of parent drug 
to metabolite is minimised at this time (Robinson et al, 
1983). It has been suggested that the use of a sample 
collected six hours after an oral dose (measured by 
HPLC) may be more useful than a trough sample in 
preventing toxicity and rejection (Cantarovich et al,
1988). Recently, an alternative approach to 
cyclosporin monitoring using a pharmacokinetic strategy 
has been proposed (Kahan and Grevel, 1988; Grevel et al,
1989) and they suggest that the use of AUC measurements 
is more useful that single trough concentration 
measurements. The disadvantage of such an approach is
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Table 1.3 Suggested therapeutic ranges for cyclosporin 
using different analytical techniques (24 hour trough 
samples, renal transplant patients)
Method Matrix Range(ug/1) Reference
HPLC Whole blood 100-200 Najarian et al 
1985.
RIA
(non-specific)
Whole blood 200-800 Irschik et al, 
1984.
RIA
(non-specific)
Serum 100-250 Kahan et al, 
1984.
RIA
(specific)
Whole blood 95-205 Kwan et al, 
1987.
47
the number of samples required (approximately 28 samples 
in the first 5 days and a further 6 samples three days 
after any dose change).
An alternative pharmacokinetic approach to dosage 
adjustment is Bayesian estimation (Sheiner et al, 1979; 
Sheiner and Beal, 1982; Kelman et al, 1982), which uses 
only one or two concentration measurements in a dosage 
interval to estimate the most likely set of 
pharmacokinetic parameters for an individual patient. 
This method requires an accurate record of doses and 
samples but does not require that the patient is at 
steady state. This technique (described more fully in 
Chapter 3) has been successfully applied to a number of 
drugs. Kahan et al (1986b) have reported that Bayesian 
estimation may be a useful method for estimating 
cyclosporin pharmacokinetic parameters, but Grevel 
(1988) cautions that the degree of intra-individual 
variability may compromise the ability to successfully 
forecast cyclosporin concentrations.
1.7 AIMS OF THESIS
This thesis presents cyclosporin pharmacokinetic 
parameters obtained by Bayesian estimation in renal 
transplant patients and these are used to explore 
sources of inter-and intra-individual pharmacokinetic 
variability. A study in patients with liver transplants 
attempts to quantify the intra-individual variability
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generated by the presence or absence of external biliary 
drainage.
49
CHAPTER 2
BIOCHEMICAL ANALYSIS
2.1 BACKGROUND
This chapter will discuss the various analytical 
techniques available to measure cyclosporin 
concentrations and the advantages and disadvantages of 
each method. The method used in this thesis will be 
described and validation of the method will be 
presented. Throughout this chapter cyclosporin will be 
described as cyclosporin A in order to differentiate it 
from the internal standard in the HPLC assay, 
cyclosporin D.
An early technique used to measure cyclosporin A in 
plasma and urine was high performance liquid 
chromatography (HPLC; Niederberger et al, 1980). This 
method, which uses cyclosporin D as an internal., 
standard, has a limit of detection of 20ug/l but its use 
in routine clinical practice is limited by the length of 
time required to analyse samples. Improvements in HPLC 
methods now involve either extensive sample preparation 
and relatively simple chromatography (Sawchuck and 
Cartier, 1981) or more straightforward extraction 
followed by complex chromatography (Smith and Robinson, 
1984). The most important feature of HPLC is its 
specificity for cyclosporin A.
In an attempt to overcome the disadvantages of HPLC 
and to provide a method suitable for clinical use, a 
radioimmunoassay (RIA) was developed (Donatsch et al,
1981). This has a similar limit of detection to the HPLC
50
method but is faster and requires less outlay on 
expensive equipment. The problem with RIA is that until 
1987, the antibody used in the assay was not specific 
for cyclosporin A and measured both parent drug and some 
of its metabolites. In spite of this, its speed, ease 
of operation and small sample volume requirement meant 
that this method was favoured in routine laboratories. 
The use of a trough sample (i.e. a sample taken before a 
dose) was thought to minimise variability in the ratio 
of parent drug:metabolites and this was considered 
adequate for routine patient monitoring (Robinson et al, 
1983). However, in patients with liver dysfunction or 
in liver transplant recipients where cyclosporin A 
metabolism is disturbed, the use of both HPLC and RIA 
may be appropriate (Burckart et al, 1986a). In these . 
patients RIA results do not provide an adequate measure 
of the concentration of cyclosporin A.
The recent development of a specific antibody for 
cyclosporin A has produced RIA results which are claimed 
to be comparable to those of HPLC (Schran et al, 1987) . 
Since this assay combines the speed and ease of the non­
specific RIA with the specificity of HPLC, it is likely 
that this will be the method of choice in the future for 
both clinical and research work. Despite claims that 
this assay is specific for cyclosporin, recent work has 
shown that concentrations determined by this assay are 
10-20% higher that those obtained by HPLC (Speck et al, 
1989) .-
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Little is known, however about the toxic and 
immunosuppressive properties of the metabolites and some 
centres may continue to use the non-specific assay as a 
measure of cyclosporin A metabolism. Another recent 
development is a fluorescence polarisation immunoassay 
(Abbott TDx) which is a non-specific assay for 
cyclosporin A (Schroeder et al, 1988). HPLC continues 
to be a useful method for large scale pharmacokinetic 
studies where rapid throughput of samples is not 
required and where specific measurement of metabolites 
is of interest.
The choice of sample matrix is controversial since 
cyclosporin is highly bound to erythrocytes and to 
plasma proteins. At 37°C, 58% of the drug is bound to 
erythrocytes, 9% is bound to leukocytes and 33% is 
distributed within the plasma (Lemaire and Tillement,
1982). At lower temperatures, cyclosporin diffuses from 
plasma into blood cells (Niederberger et al, 1983) . 
Consequently an apparent fall in cyclosporin plasma 
concentrations to approximately 50-60% of the 
concentration at 37°C is seen when sample separation is 
carried out at 21°C (Follath et al, 1983). An 
additional problem with the use of plasma as the matrix 
is that variations in haematocrit will affect the 
proportion of drug in plasma (Rosano, 1985? Niederberger 
et al, 1983). As a result, cyclosporin is usually 
measured in whole blood rather than in plasma (Wenk et
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al, 1983). By using whole blood, the effect of changes 
in temperature and haematocrit can be overcome (Shaw et 
al, 1987).
2.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
As detailed pharmacokinetic studies were the focus 
of this thesis, all data in Chapters 4, 5 and 7 are based 
on the HPLC analysis of cyclosporin in whole blood and 
this section will describe the method used and its 
validation. Data in chapter 6 are based on the specific 
RIA measurements and validation of this method is given 
in Appendix 1.
2.2.1 Chemicals and Equipment
The manufacturers and suppliers of all chemicals, 
reagents and equipment are listed in Tables 2.1(i) and 
(ii).
2.2.2 Preparation of Solutions and Standards
(a) Cyclosporin A
5mg of cyclosporin A were dissolved in 10ml 
methanol. This was then diluted 1:1 with water. A 
50:50(v/v) solution of acetonitrile in water was used to 
prepare solutions of cyclosporin A for spiking standards 
in whole blood.
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Table 2.1 (i) Chemicals and Reagents used in HPLC assay
Chemical Supplier
Cyclosporin A Sandoz Ltd, Basle, 
Switzerland
Cyclosporin D Sandoz Ltd, Basle, 
Switzerland.
Far UV Grade Acetonitrile Fisons pic, Loughborough, 
Leicestershire.
HPLC Grade Hexane May and Baker Ltd, 
Dagenham, England.
HPLC Grade Methanol May and Baker Ltd, 
Dagenham, England.
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Table 2.1(ii) Equipment used in HPLC assay
Equipment Model and Supplier
Spherisorb methyl 5um Jones Chromatography Ltd,
matrix column (5cm x 4.6mm) Mid Glamorgan, Wales.
Spherisorb C-18 0DS2 column 
(15cm x 4.6mm)
Pre-column filter frit 
(2um)
Column block heater 
HPLC pumps (2)
Automatic Injector 
Valve station
Gradient controller
Ultra violet detector
Integrator
HPLC Technology Ltd, 
Macclesfield, England.
Upchurch Scientific, Inc 
Washington.
Model TC 860
HPLC Technology Ltd,
Macclesfield, England.
Model 510 
Millipore, Waters 
Chromatography Division, 
Massachusetts.
WISP Model 710B
Waters Automated Valve 
Station
Model 680
Model SPD-6A 
Shimadzu Corporation, 
Kyoto, Japan.
Model Chromatopac C-R3A, 
Shimadzu Corporation, 
Kyoto, Japan.
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(b) Cyclosporin D (internal standard)
5mg of cyclosporin D were dissolved in 10ml methanol 
and diluted with acetonitrile to give a solution of 
500ug/l.
(c) Calibration Standards and Controls
Blank whole blood was spiked with 
cyclosporin to give calibration standards of 50, 100,
500 and 1000ug/l cyclosporin A in whole blood. Controls 
of 0, 20 and 200ug/l cyclosporin A in whole blood were 
also prepared.
(d) Mobile Phases
Acetonitrile and water were filtered and measured 
individually and then mixed thoroughly in the following 
proportions.
55:45 acetonitrile:water 
70:30 acetonitrile:water 
90:10 acetonitrile:water
2.2.3 Methods
(a) Pre-chromatographic Extraction
lml of whole blood (calibration standard, control 
or unknown sample) was pipetted into a test-tube, 0.2ml 
methanol added and vortexed for 5 seconds. 1.2ml
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internal standard solution was added to each tube. The 
tubes were capped, vortexed and incubated at 37°C for 
two hours. They were then vortexed and centrifuged for 
15 minutes. Between 1 and 1.2ml of the upper layer was 
transferred to a conical glass tube, 1ml of hexane added 
and vortexed for 30 seconds. These tubes were placed in 
a -70°C freezer for 10 minutes and then thawed at 37°C 
for 10 minutes. 1ml of the lower layer was transferred 
to a clean glass conical tube, 0.3ml water added, 
vortexed and placed in the 37°C water bath for 10 
minutes to evaporate any remaining hexane. The tubes 
were centrifuged for 5 minutes and 1.2ml supernatant 
transferred to WISP injection vials.
(b) Chromatography
The HPLC equipment was set up as shown in Figures 
2.1(i) and (ii). A 15cm C-18 ODS2 column was used as 
the analytical column. The pre-column was a Spherisorb 
methyl 5um cartridge column. A pre-column filter of 
frit size 2um was placed in front of the pre-column.
The pre-column filter and both chromatography columns 
were placed in the column block heater at 72°C in order 
to improve peak shape (Bowers and Matthews, 1985) . The 
automated valve station was used to control the 
direction of flow of mobile phase and to operate the 
detector and integrator. It had seven switches (as 
shown in Figure 2.2): the function of each switch is
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Figure 2.1 (i) Diagram of equipment used for HPLC
analysis of cyclosporin
AUTOMATED
GRADIENT
CONTROLLERUV DETECTOR
AUTOMATED 
VALVE STATION
WISP
AUTOSAMPLER
PUMP B PUMP A
INTEGRATOR
Column 2
COLUMN HEATER
Figure 2.1 (ii) Photograph of equipment used for HPLC
analysis of cyclosporin
listed in Table 2.2. The automated gradient controller 
controlled the timing of the switches on the valve 
station by use of a Time Program and a Gradient Program.
At the start of each new run the gradient 
controller was reprogrammed. This was done by altering 
the set up of the equipment slightly so that eluent from 
the pre-column passed directly to the integrator. A 
standard solution containing equal amounts of 
cyclosporin A and D was injected onto the pre-column in 
triplicate and the time from the start of the 
cyclosporin A peak to the end of the cyclosporin D peak 
calculated. This time period was called the "cutting 
time" and was entered in the time program of the 
gradient controller. The time program also controlled 
auto-zeroing of the detector, starting the integrator 
and equilibrating the system in preparation for the next 
injection. The gradient controller had a gradient 
program to control the flow rate of the mobile phase 
through the columns. Typical time and gradient programs 
are shown in Tables 2.3 and 2.4.
2.2.4 Results
(a) Chromatography
Cyclosporin A and D were separated by the method 
described. The quality of separation was highly 
dependent on the age of the columns. The pre-column 
lasted for approximately 300 injections and was replaced 
when interfering compounds in the blood extract were
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Table 2.2 Use of switches on Waters Automated Valve 
Station
Switch ON (=1) OFF (=0)
1 eluent from column 1 is 
directed onto column 2
eluent from column 1 
is directed to waste
2 eluent from column 2 
passes through detector
eluent from column 2 
is directed to waste
3 mobile phase for 
column 2 is 55:45
mobile phase for 
column 2 is 70:30
4 allows switch 5 
to function
mobile phase for 
column 1.is 55:45
5 mobile phase for 
column 1 is 70:30 
if switch 4 is on
mobile phase for 
column 1 is 90:10 
if switch 4 is on
6 Pulse on, off for 0.05 minutes to autozero 
detector
7 Pulse on,off for 0.01 minutes to start 
integrator
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Figure 2.2 Use of the seven switches available on the 
automated valve station used in HPLC assay
90%70%55%
SWITCHES 
4 and 5
PUMP A
WISP column heater
Column Column 2
WASTE SWITCHSWITCH
55% ) ( 70%
PUMP B
WASTE
Switch 3
WASTEDETECTOR
INTEGRATOR Switch 7Switch 6
Table 2.3 Typical time program set on Waters
Automated Gradient Controller
Time
(minutes)
Switch Action Result of action
0.01 5 0
5.00 1 1 CUTTING TIME (determined
10.50 1 0 earlier),
10.51 4 1 90:10 mobile phase to 
clean column 1.
10.52 2 1 eluent from column 2 
directed to detector
10.53 3 0 70:30 mobile phase to 
column 2 to elute 
cyclosporin A and D
15.50 6 1 0.05 minute pulse to
15.55 6 0 autozero detector
15.60 7 1 0.01 minute pulse
15.61 7 0 to start integrator
19.00 4 0 55:45 mobile phase to 
re-equilibrate column 1
26.00 3 1 55:45 mobile phase to 
re-equilibrate column 2
26.01 2 0 eluent from column 2 
directed to waste
NOTE: (i) 0 = off, 1 = on.
(ii) integrator stopped by setting "stop-time" on
integrator
(iii) the time of the next injection was determined
by the analysis time set on the WISP.
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Table 2.4 Typical gradient program set on Waters
Automated Gradient Controller
Time
(minutes)
Flow rate 
(ml/min)
Pump A 
(% of total)
Pump B 
(% of total)
0.00 2.5 60 40
10.50 2.5 60 40
10.51 4.0 50 50
11.50 5.0 50 50
11.51 5.0 60 40
22.50 5.0 60 40
22.51 6.0 50 50
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able to pass onto the analytical column with cyclosporin 
A and D. By replacing the pre-column regularly, the 
analytical column lasted for approximately 1500 
injections. As the analytical column aged, the 
cyclosporin A and D peaks became broader and were less 
well resolved from each other. When peak shape and 
separation became unacceptable (it became difficult to 
tell where one peak ended and the other began) a new 
analytical column was installed. The effect of age on 
the analytical column is shown in Figure 2.3.
(b) Calibration
A calibration line was constructed for each run. 
Standards of 50, 100, 500 and 1000ug/l cyclosporin A in 
whole blood were assayed in duplicate. Peak areas of 
the cyclosporin A and D peaks were measured by the 
integrator and the ratio of cyclosporin A : cyclosporin 
D calculated. The calibration line was constructed by 
plotting the known concentration of the standard on the 
x-axis and the corresponding ratio on the y-axis. The 
best fit line of this plot was determined by linear 
regression and was used to determine concentrations of 
unknown and quality control samples. A typical 
calibration line is shown in Figure 2.4. Figure 2.5 
shows two typical chromatograms of unknown samples and 
their concentrations calculated from the calibration 
line. All unknown and quality control samples were
62
Figure 2.3 Effect of age of the analytical column on
peak shape of cyclosporin A and cyclosporin D
(i) new analytical column (extract of blood sample 
spiked with 100ug/l cyclosporin A)
(ii) analytical column after approximately 1000
injections (extract of blood sample spiked with 
100ug/l cyclosporin A)
Figure 2.4 Typical calibration line for calculation 
of concentration of cyclosporin A in 
unknown and control samples
y = 0.00145 x - 0.0086 
r = 0.997
Peak area ratio
cyclosporin A
cyclosporin
0 200 400 600 800 1000 1200
Concentration of Cyclosporin (pg/i)
Figure 2.5 Chromatograms of samples containing unknown 
concentrations of cyclosporin A
(i) calculated to contain 76ug/l cyclosporin A
(ii) calculated to contain 924ug/l cyclosporin A
assayed in duplicate.
(c) Specificity
Extraction of whole blood samples known to contain 
no cyclosporin A was carried out to ensure that no 
constituents of blood interfered with the assay. This 
was done using a blood sample to which was added the 
vehicle of the internal standard solution (i.e., no 
cyclosporin A or D) and this was a "double blank". 
Another blood sample was extracted in the usual way and 
was termed a "single blank" (ie contained internal 
standard only). The double blank check was carried out 
on blood to be used for preparation of standard 
calibration controls. The single blank sample was 
assayed with each run to ensure that specificity for 
cyclosporin A was being maintained. Chromatograms of 
these samples are shown in Figure 2.6 (i) and (ii). No 
peaks co-eluted with cyclosporin A or cyclosporin D in 
the blank blood used to prepare pooled samples of 
standards.
In addition, several drugs which the patients in 
the study were known to be taking were dissolved in 
appropriate solvents and added to blank whole blood.
The blood used to prepare calibration standards and 
controls was obtained from patients known to be taking a 
variety of drugs (other that cyclosporin) and no 
coeluting peaks were seen.
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Figure 2.6 Chromatograms of controls used in HPLC assay
(i) 'double blank' (ii) 'single blank'
blood extract blood extract
(iii) blood extract spiked
with 20ug/l cyclosporin A
(iv) blood extract spiked
with 200ug/l cyclosporin A
(d) Limit of- Detection
A 20ug/l cyclosporin A control sample was included 
in each run to ensure that this concentration could 
always be detected. The lowest detectable concentration 
was defined as that producing a signal (peak) of five 
times the baseline noise. A typical chromatogram of 
this concentration is shown in Figure 2.6 (iii).
(e) Linearity
The assay was validated for linearity over the 
range 20 to 1000ug/l cyclosporin A. Unknown or quality 
control samples found to contain concentrations above 
1000ug/l were diluted with blank whole blood and re­
assayed. Concentrations below 20ug/l were recorded as 
<20ug/l. .. '
(f) Extraction Efficiency
The percentage of cyclosporin extracted from a 
blood sample was investigated by comparing peak areas of 
extracted samples with direct injection of an equivalent 
amount into.the system. The extraction efficiency of 
the assay for- a concentration of 200ug/l cyclosporin A 
was 56.2%. :
(g) Precision and Quality Control
Inter-assay precision was determined by comparison 
of peak area ratios of 12 consecutive calibration lines
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and the results of this are shown in Table 2.5(i). In 
addition, a quality control sample containing 200ug/l 
cyclosporin A (Figure 2.6(iv)) was included in each run 
of the assay. Inter-assay precision calculated from 
this sample is shown in Table 2.5 (ii).
Intra-assay variability was determined by assaying 
each calibration standard six times together with six 
samples from a pool of unknown concentration. In 
addition the 200ug/l quality control sample was assayed 
twelve times and intra-assay precision of the 
calculated concentrations determined. The results of 
this are shown in Table 2.6(i) and (ii).
(h) External quality control
Specificity of the assay from constituents of blood 
was determined by running blank samples. It was, 
however, difficult to prove that none of the cyclosporin 
metabolites were interfering with the assay since only a 
few were available commercially. Twelve samples were 
supplied by the United Kingdom Cyclosporin Quality 
Assessment Scheme and were assayed by this method and 
also by an established method at another centre. The 
results of this are shown in Table 2.7. It can be seen 
that the results from this centre and the established 
centre are comparable.
In addition three samples were assayed each month 
which were also supplied by the same scheme and the
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Table 2.5 Inter-assay precision of HPLC assay
(i) Comparison of peak area ratios of calibration 
standards
Concentration Coefficient of
(ug/1) variation (%)
50 15.5
100 13.6
500 10.3
1000 11.7
(ii) Quality control sample included in each run 
Known Calculated
Concentration Concentration CV n
(ug/1) (ug/1) (%)
200 192 7.3 61
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Table 2.6 Intra-assay precision of HPLC assay
(i) Comparison of peak area ratios of calibration 
standards
Concentration
(ug/1)
CV
(%)
n
50 5.7 6
100 3.4 6
500 3.6 6
1000 4.4 6
.i) Calculated concentration of known and unknown 
cyclosporin pooled samples
Concentration Calculated
concentration
CV n
(ug/1) (ug/1) (%)
200 204 2.1 12
Unknown 528 3.6 6
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Table 2.7 Measured concentrations of 12 unknown
samples and comparison of results with an 
"Established Centre” using the same assay
Sample Measured
(ug/1)
Actual
(ug/1)
"Established 
Centre"(ug/1)
1 439 500 526
2 0 0 0
3 179 unknown 212
4 891 1000 976
5 202 unknown 232
6 240 250 268
7 0 0 0
8 453 500 528
9 175 unknown 280
10 897 1000 1100
11 239 250 272
12 185 unknown 230
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results of this are'shown in Figure 2.7. No absolute 
value was known for these samples since, with the 
exception of samples containing no cyclosporin A, they 
were usually prepared by pooling patient samples. The 
results do not therefore give a measure of accuracy. 
They do, however, provide a comparison with other 
centres using similar analytical techniques ie 
measurement of cyclosporin A in whole blood using HPLC. 
From Figure 2.7 it can be seen that the results from 
this assay generally fall within one standard deviation 
of the mean of the other centres. On each occasion 
where a blank sample (ie containing no cyclosporin A) 
was included, this was correctly identified.
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CHAPTER 3
DATA ANALYSIS
3.1 INTRODUCTION
In this chapter, the various pharmacokinetic and 
analytical techniques used throughout this thesis will 
be discussed. A brief description of relevant 
pharmacokinetic principles and equations will be 
followed by a discussion of the statistical methods 
used. Computer programs used to analyse the data will 
also be described.
3.2 PHARMACOKINETICS
3.2.1 Background
Pharmacokinetics is the mathematical description of 
the movement of a drug throughout the body? a series of 
equations describes the time course of absorption, 
distribution and elimination of a drug. Such a 
quantitative description is of great importance because 
there is often a close relationship between drug 
concentration and effect. In a clinical setting, 
knowledge of the pharmacokinetics of a drug is of 
particular interest for drugs which have a narrow 
therapeutic range and where efficacy and/or toxicity are 
closely related to concentration.
3.2.2 Pharmacokinetic parameters
The two most useful parameters to describe the 
pharmacokinetic behaviour of a drug are clearance (Cl) 
and volume of distribution (V). Clearance is defined as
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the volume of blood, plasma or serum from which drug is 
completely removed per unit of time and in this thesis 
is measured in units of litres per hour (1/h).
Knowledge of drug input (ie dose) and clearance enables 
calculation of the average concentration at steady 
state, Css, (Equation 3.1).
_  Dose rate
Css =-------- ---------  Equation 3.1
Clearance
Volume of distribution relates the amount of drug 
in the body to the measured concentration and is 
generally measured in litres (1). Knowledge of volume 
enables calculation of the concentration of drug 
immediately following a bolus injection before any 
elimination has taken place. The ratio of clearance to 
volume expresses the fractional rate of removal of a 
drug, ie the elimination rate constant (ke) (Equation 
3.2) the units of which are usually per hour (h"1).
Cl
ke = —  Equation 3.2
V
3.2.3 Oral absorption
When a drug is administered by a route other than 
the intravenous route, the rate and extent of absorption 
will affect the concentration of drug in the systemic 
circulation. Many drugs, including cyclosporin, are
most commonly given orally. The rate of absorption can 
be described by a first order absorption rate constant 
(ka) which means that the rate of absorption is 
proportional to the amount of drug at the absorption 
site (ie the gut in the case of oral administration).
The extent of absorption is known as bioavailability (F) 
and is defined as the fraction of the dose of parent 
drug reaching the systemic circulation. The oral 
absorption of a drug is most commonly described by a 
first order process (as above) but absorption of a few 
drugs may be better described by an apparent zero order 
process, ie the rate of absorption is independent of the 
amount of drug at the site of absorption.
3.2.4 Measurement of Bioavailabilitv
The area under the concentration-time curve (AUC) 
is a useful method of estimating the extent of 
absorption of an orally administered drug. 
Bioavailability can be calculated by comparing the AUC 
of an oral dose with that of an intravenous dose.
The standard method of measuring AUC is by the 
linear trapezoidal rule (Gibaldi and Perrier, 1975).
AUC is calculated by dividing the concentration-time 
curve into a series of trapezoids and calculating the 
area of each of the trapezoids as in Equation 3.3.
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Area of trapezoid = 0.5 (Cj_+C^+1) (t^+1 -t^)
Equation 3.3
(for n measured concentrations where i=l,2 .... .n-l'j 
C^ is drug concentration at time (t^) .
AUCq is the sum of the trapezoids from time zero to time 
T (=tn).
When a patient is at steady state, AUC measured 
from time of administration of the dose to the end of 
the dosage interval (AUCq) is equal to AUC from time 
zero to infinity (AUCq5) for a single dose of the drug.
If the patient is not at steady state, the influence of 
previous doses is taken into account by estimation of 
the terminal elimination rate constant and calculation 
of the area due to previous doses.
Bioavailability is calculated from equation 3.4
AUCq5 (oral) Dose(iv)
F = --------- --- x --------— —  Equation 3.4
AUC^ (iv) Dose(oral)
where AUCq5 expresses the area under the curve from time 
zero to infinity.
3.2.5 Compartmenta1 models
The concentration-time profile of a drug is 
commonly represented by a system of compartments. These 
compartments have no physiological or anatomical  ^
meaning; rather they refer to organs or tissues for 
which rate of uptake and clearance are similar. It is 
assumed that the concentration of drug is the same
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throughout all compartments at equilibrium. The rates 
of transfer between compartments are assumed to obey 
first order kinetics. Although compartments have no 
physiological meaning, they provide a useful method of 
defining the distribution and elimination processes 
which contribute to the plasma concentration time 
profile. Drug concentration in any compartment can be 
described by a series of differential equations.
The simplest model is the one compartment model 
which assumes that the body is a homogeneous unit from 
which drug elimination is first order. If first order 
absorption is also assumed, then the differential 
equation describing the pharmacokinetics of the drug is
dA/dt = kaG - keA Equation 3.5
where G is the amount of drug in the gut, ka is the 
absorption rate constant, ke is the elimination rate 
constant and A is the amount of drug in the body at time 
t. This is shown diagrammatically in Figure 3.1. 
Equation 3.5 can be solved by the method of Laplace 
transformation (Appendix 2) to give Equation 3.6.
ka DF . . , .
C  -------- — - (e e - e a ) Equation 3.6
V(ka-ke)
where C is the concentration at time t and D is the oral 
dose.
A two compartment model can be represented as shown 
in Figure 3.2 and is described by a biexponential
7 A
Figure 3.1 Diagrammatic representation of one compartment model
assuming first order absorption
GUT (G)
Figure 3.2 Diagrammatic representation of two compartment model
assuming first order absorption
\ v
12
21
10
A2
GUT (G)
A1
equation. This model assumes that there is a central 
compartment from which the drug distributes into a 
second compartment. The concentration-time profile for 
a drug exhibiting two compartment pharmacokinetic 
behaviour shows an initial decline in concentration 
which represents both distribution and elimination 
followed by a second slower decline.
The differential equations which describe this 
model are
cLZ^/dt = kaG - k12Ai “ ^ioAl + ^21a2 Equation 3.7
dA2/dt = k12A1 - k21A2 Equation 3.8
where A-^  and A2 are the amounts of drug in compartments 
1 and 2 respectively. The rate constants k10, k12 and 
k21 represent the rate of elimination from the central 
compartment, the rate of transfer from the central 
compartment to the peripheral compartment and the rate 
of transfer from the peripheral compartment to the 
central compartment respectively. These equations are 
also solved by Laplace transformation (Equation 3.9).
and elimination and is the volume of the central 
compartment. The method of solving these equations by 
Laplace transformation is given in Appendix 2.
C
Equation 3.9.
where a  and are rate constants describing distribution
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3.3 STATISTICAL TECHNIQUES
3.3.1 General comments
Appropriate statistical techniques were used to 
analyse the data. Calibration lines in Chapter 2 were 
calculated by simple linear regression. Standard t 
tests and analysis of variance were used, and these will 
be discussed in the relevant areas of the thesis.
3.3.2 Multiple Linear Regression
Simple linear regression assumes a linear 
relationship between one dependent variable and one 
independent variable (as in the relationship between 
drug concentration and peak area ratio in calibration 
lines described in Chapter 2). Multiple linear 
regression can be used to describe the relationship 
between a dependent variable and a number of independent 
variables and is used in this work to relate changes in 
pharmacokinetic parameters to several demographic and 
clinical variables. The multiple linear regression 
equation is
y = a + h^X-L + b2X2 + ...... + bnXn Equation 3.10
where X<l to Xn are the different independent variables, 
and a and b2 - bn are the parameters of the model. If 
more than one observation is made in each subject the 
observations can not be assumed to be independent and 
the multiple linear regression analysis must also test
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for individual subject effects, ie individual intercept 
parameters (a^) or individual slope parameters (bf) in 
Equation 3.10.
Multiple linear regression is used to determine the - 
parameters of a model and to test the influence of 
inclusion of various factors in the model. The 
significance of each factor on the dependent variable is 
tested by comparing the residual sum of squares obtained 
when the factor is present or absent. Adding in more 
parameters to the model will result in reduced residual 
sums of squares and an apparent improvement in the fit.
The aim of multiple linear regression is to obtain the 
simplest model which adequately explains the variability 
in the data. Although inclusion of an additional 
variable may suggest that there is an apparent 
improvement in the fit, this improvement may not be 
statistically significant. Significance of adding more 
variables to the model is tested by using the General 
Linear Test (F ratio test) as follows
RSSQr - RSSQf / dfr -dff
F =    Equation 3.11
RSSQf / dff
r = reduced model
f = full model
dfr = degrees of freedom of reduced model 
dff = degrees of freedom of full model 
RSSQ = residual sum of squares
Multiple linear regression can be carried out by
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initially using every possible known parameter and 
testing for a significant reduction in the F value if a 
parameter is removed (backward stepping). Alternatively 
the simplest model can be used initially and the 
significance of adding in parameters one at a time 
tested (forward stepping). The latter method was used 
in this thesis.
The fraction of the total variability which is 
explained by the model is described by the coefficient 
of determination (R2).
RSSQ
R = 1 -   Equation 3 .12
ssQtotal
The inclusion of further parameters in a model will 
almost always result in an increase in the value of R2as 
seen by a reduction in the residual sum of squares. It 
may therefore be helpful to use a stopping rule which 
takes into account the improvement in R2 along with the 
number of parameters in the model. In this thesis, 
Adjusted R has been used which is calculated as follows
(N-l)R2 - P
Adjusted R  -------   Equation 3.13
N - P - 1
where N = number of data points and P = number of 
variables.
3.3.3 Non-linear Regression
When using linear regression the relationship 
between the dependent and independent variables is
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assumed to be linear. The dependent or independent 
variable may be transformed, eg to a logarithmic scale 
to obtain linearity. Typically, non-linear regression 
is used when concentration-time data are collected 
during the course of a pharmacokinetic study. There is 
no unique solution to the values of the parameters of 
the model. Such data are generally analysed by 
computer, where initial estimates of the parameters are 
required and these are progressively altered by an 
iterative procedure until the best set of parameters is 
obtained. This is the point at which the difference 
between two successive objective values is less than a 
pre-defined limit. The best set of parameters is that 
where minimisation of the objective function occurs.
The simplest objective function is Ordinary Least 
Squares (OLS) shown in Equation 3.14.
n
Obj (OLS) = “ ^i )2 Equation 3.14
i = 1
where c^ is the measured concentration and c^ is the 
concentration predicted by the model and its parameters. 
OLS assumes that the error on each measurement is 
similar. An alternative is to use Weighted Least 
Squares (WLS) which weights each observation according 
to the associated variance of the measurement such that 
more weight is placed on those points about which there 
is greater confidence. OLS and WLS are limited by the 
need to make assumptions about the error on each 
measurement in advance. An alternative weighting scheme
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is extended least squares (ELS) (Sheiner, 1983) which 
estimates the parameters of the model and also the 
parameters of a variance model. The objective function
used in ELS is shown in Equation 3.15
n
Obj (ELS) = ^ ( c ^  - c^)2 / v^ + lnv^ Equation 3.15
i =1
where c^ is an observation which represents the true 
value, c^ and v^ is the variance. The optimal set of 
parameters is the one which minimises the objective 
function as before.
The computer program NONMEM (Non-linear Mixed 
Effects Model) (Beal and Sheiner, 1979) was originally 
devised to analyse data where only a few measurements 
are available per subject, but from a large number of 
subjects. The program uses an extended least squares 
fitting procedure and estimates the parameters of the 
chosen pharmacokinetic model and also the parameters of 
an appropriate variance model which describes the inter- 
and intra-subject variability of the model.
In the present work NONMEM is used to examine 
relationships between pharmacokinetic parameters which 
have already been determined and certain independent 
variables of interest, such as creatinine concentration 
or liver function. NONMEM allows both linear and non­
linear relationships to be explored whereas multiple 
linear regression described above assumes a linear 
relationship between the dependent and independent
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variables.
Three input files are required to run NONMEM.
These are (i) the data file which contains the data and 
the independent variables (or covariates), (ii) the PRED 
file which is a FORTRAN subroutine and defines the 
structural and variance models and (iii) the control 
file which contains information on the organisation of 
data in the data file, the starting values (and upper 
and lower limits) of the parameters and instructions on 
the presentation of results, tables and graphs. PRED 
files used in this thesis are shown in Appendix 3.
The parameters of the structural model, f o r
an individual are represented by the population mean, 
plus the deviation from the mean which is relevant to 
the individual rj^  (where r]w represents inter-subject 
variability), thus
0ki = + *7ki Equation 3.16
Values of 7]^ are assumed to be normally distributed with 
mean of 0 and variance of ak2 . Alternatively it can be 
assumed that the inter-subject variability is 
proportional to the value of d which avoids the 
possibility of 0 or negative parameter values and is 
therefore more realistic in a physiological setting ie.
ln(0ki) = ln(0k) + ??ki Equation 3.17
In the PRED files (Appendix 3), the parameters 
(THETA 1, THETA 2 etc) are defined. The structural model is
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the F function. The G functions define the statistical 
nature of the inter-subject variability and are the 
first derivatives of the function with respect to each 
ETA. The H function defines the statistical nature of 
the intra-subject variability (€ij)« The value of e^j 
is assumed to be normally distributed with a mean of 0 
and variance cr£ and assumes a constant error model ie no 
covariance is allowed between r^and e.
Comparison of Models
Comparison of NONMEM models is based on the 
objective function. Hierarchical models can be compared 
using a chi-squared test with degrees of freedom equal 
to the difference in the number of parameters. For non- 
hierarchical models, (eg in Section 5.2, where all 
models have the same number of parameters) model 
comparison is based on the objective function, on the 
variances associated with each parameter, and on 
examination of residual plots.
3.4 BAYESIAN ESTIMATION
In a clinical setting, a blood, plasma or serum 
sample is often collected from an individual patient for 
the measurement of a drug concentration, and dosage 
adjustments made on the basis of that measurement. In 
order that accurate interpretation of the results may be 
made, steady state conditions must have been attained
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(ie the patient must have been receiving the same dose 
for at least 5 half lives of the drug). The consequence 
of any change in dose cannot be assessed 
pharmacokinetically until the patient is again at steady 
state. It is likely that in an acute care hospital ward 
the dose of a drug will be frequently altered, based on 
clinical requirements and in such situations it is 
difficult to interpret a single measured concentration. 
It would be possible to estimate pharmacokinetic 
parameters for an individual patient using non-linear 
regression, but this would require collection of many 
blood samples and is largely impractical.
An alternative is to employ Bayesian estimation. 
This technique is based on Bayes' Theorem (Wonnacott and 
Wonnacott, 1977) and the principle of Maximum Likelihood 
Estimation (Edwards, 1976). Bayesian estimation uses 
measured concentrations in combination with previously 
determined population pharmacokinetic parameters and 
their variances. Revised individual patient parameters 
are then obtained (Sheiner and Beal, 1982). Bayesian 
estimation therefore uses both measured concentrations 
and population pharmacokinetic information to estimate 
the most likely set of pharmacokinetic parameters in an 
individual patient. The background to Bayesian 
estimation is outlined below (Sheiner and Beal, 1982).
A concentration measurement (Cj) is a function of 
the parameters of the model used (0^), independent 
variables including time (t) and dose (D) and an error
term ej, which accounts for assay error, model 
misspecification and random intra-subject variability. 
This can be expressed as follows
Cj = f(0k ,D,t) + fj Equation 3.18
The error is assumed to be normally distributed with 
mean 0 and variance Oj which is known.
The population parameter estimates (0k) are 
obtained from a population study of the particular drug 
or from published literature. Each individual parameter 
estimate (0k) is defined as the population parameter 
(0k) plus a random error (77 k) . The random error is 
assumed to be normally distributed with a mean of 0 and 
variance equal to the population variance.
The Bayesian procedure minimises the following 
objective function (Equation 3.19).
function has two components? the first part attempts to 
minimise the squared errors between observed 
concentrations and predicted concentrations while the 
second part of the equation minimises the squared errors 
between population parameters and revised parameters. 
Minimisation of this function produces a revised set of 
parameters and variances which are the most likely set
Equation 3.19
where crk2 , crj2 and 0k are pre-defined. The objective
for that individual patient. When there are no 
concentration measurements the parameters are those of 
the population. As concentration measurements become 
available the population parameter estimates become less 
important. A time factor is also used which gives less 
weight to more distant concentrations. This time factor 
is 15% of the concentration multiplied by 1.01T where T 
is time elapsed since the measurement (Peck et al, 1980) 
i.e.
(7j = 1.01T x 0.15Cj Equation 3.20
The use of a Bayesian estimation program has been 
evaluated for theophylline (Sheiner and Beal, 1982) and 
digoxin (Whiting et al, 1984a). A package of computer 
programs which is based on Bayesian theory has been 
written (Kelman et al, 1982). This package has been 
adapted for the studies in this thesis. A one 
compartment model with first order absorption for an 
orally administered drug is used and estimates ka , Cl 
and V. A two compartment version estimates ka , Cl, V^, OL 
and jg. The program assumes that there is no consistent 
or underlying change in the parameters throughout the 
period of drug monitoring. Both the one and two 
compartment versions of the Bayesian program are 
evaluated in Chapter 4.
During the course of this work a further version of 
the Bayesian program was developed. This version allows 
for a consistent change in pharmacokinetics by allowing
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a gradual decrease in the ratio of Cl/F. This version 
requires that the weighting function above (Equation 
3.20) is not used and that equal weight is placed on all 
concentrations independent of time. The way in which 
this version of the program works will be described in 
Chapter 6.
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CHAPTER 4
PHARMACOKINETICS OP CYCLOSPORIN IN THE FIRST TWO 
MONTHS FOLLOWING RENAL TRANSPLANTATION
4.1 INTRODUCTION
This study was designed to examine the 
pharmacokinetics of cyclosporin in renal transplant 
patients and to quantify inter- and intra-patient 
variability. Pharmacokinetic parameters were estimated 
by a standard Bayesian approach (Section 3.4) and 
validation of this method is reported.
4.2 PHARMACOKINETIC STUDY
4.2.1 Patients
Twelve consecutive renal transplant recipients were 
recruited. One patient suffered post-operative 
complications and was nephrectomized three days after 
transplantation. The other eleven were studied for 
sixty days after transplantation. Cyclosporin and low 
dose steroids were the only regular immunosuppressant 
drugs given although high dose steroids were 
occasionally required to treat acute rejection episodes. 
Patients were excluded from the study if cyclosporin had 
been administered in a previous transplant. Clinical 
details of the patients who completed the study are 
shown in Table 4.1.
4.2.2 Data collection
The demographic and clinical data listed below were 
recorded for each patient.
(i) Initially age, height, and reason for transplant
Table 4.1 Clinical details of renal transplant patients 
completing pharmacokinetic study
Patient Age Sex Weight(kg) Reason for transplant
1 50 M 92 Diabetic nephropathy
2 30 M 62 Chronic pyelonephritis
3 46 F 47 Chronic renal failure
4 55 F 80 Chronic renal failure
5 17 M 57 Chronic renal failure
6 22 M 52 Henoch-schonlein pupura
7 52 M 72 G1omerulonephritis
8 29 M 64 Obstructive uropathy
9 26 M 80 Diabetic nephropathy
10 32 M 80 Glomerulonephritis
11 28 M 56 Obstructive uropathy
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were recorded for each patient.
(ii) Throughout the study the following data were 
recorded for each patient? serum creatinine, total 
bilirubin, alanine amino transferase, albumin, 
cholesterol, haematocrit and haemoglobin. In addition 
periods of vomiting and diarrhoea were noted and patient 
weight, blood pressure and concurrent drug therapy were 
recorded over the sixty days of the study.
4.2.3 Cyclosporin therapy
Prior to transplantation each patient received an 
oral dose of cyclosporin (15mg/kg). The day of 
transplantation was designated day 0 and following 
surgery 5mg/kg cyclosporin were administered 
intravenously over six hours. All subsequent therapy 
was given orally with the exception of patient 9 on day 
10 who received intravenous cyclosporin when he was 
unable to tolerate oral therapy. Patients remained in 
hospital for between six and twenty five days after the 
transplant (mean = 14 days). During this period blood 
samples for cyclosporin assay were withdrawn immediately 
prior to each dose (trough) and at least one other 
sample was collected per dosage interval. Following 
discharge from hospital, patients attended the renal 
transplant out-patient clinic, initially daily, then 
every second day, until towards the end of the study, 
patients attended only once a week. A trough blood
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sample was withdrawn at each visit. Figure 4.1 shows a 
typical cyclosporin dosing and sampling schedule in one 
patient. Blood samples were collected in 5ml EDTA tubes 
and stored at -20°C prior to analysis. An average of 
fifty samples was collected from each patient. All 
blood samples were assayed for cyclosporin by the HPLC 
method described in Chapter 2. Although this assay was 
time consuming and not generally considered suitable for 
routine analysis of clinical samples, it was the 
analytical method of choice for pharmacokinetic studies 
because of its specificity. Any change in dose in these 
patients was made on the basis of a non-specific radio­
immunoassay which measured both cyclosporin and some 
cross reacting metabolites.
4.2.4 Data analysis
Using Bayesian estimation (Section 3.4) two 
pharmacokinetic models were investigated - a one and a 
two compartment model. The parameter starting values 
(priors) were obtained from a review of previously 
published data on cyclosporin (Ptachcinski et al, 1986). 
Population standard deviations were those recommended by 
Peck et al (1980) with the exception of volume where the 
standard deviation was set at 90% (since little 
information on volume of distribution was available).
The starting values and their standard deviations for 
both models are listed in Table 4.2. The standard
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Figure 4.1
Cyclosporin
Concentration
(n g / i )
Cyclosporin 
Dose (mg)
Typical cyclosporin dosing and sampling 
schedule in one patient
1500 n
1000 -
500 -
A  Other cones 
#  Trough cones
• •
t— j-1— j  -------- 1— i— r
0 10 20  30 40 50 60
Time post transplant (days)
900
600
100
300
Time post transplant (days)
9999955
Table 4.2 Estimates of pharmacokinetic parameters 
(sd)%used in Bayesian estimation
Parameter 1 compartment 
model
2 compartment 
model
ka 0.61T1 (50) 0.61T1 (50)
Cl 0.341/h/kg (50) 0.341/h/kg (50)
V 4.51/kg (90) *0.141/kg (90)
a 0.71T1 (50)
& 0.06h-1 (50)
* - volume of central compartment
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deviation of each concentration was set at 15% of the 
measured concentration to account for measurement error 
and model misspecification.
Bayesian parameters were estimated sequentially by 
first using concentration-time data from day 1 only, 
then days 1 and 2, days 1, 2 and 3, and so on until days 
1 to 60 were used. In this way an average of 33 sets of 
Bayesian parameters were obtained from each patient.
This series of parameter estimates was obtained with the 
standard program where progressively less weight was 
assigned to more and more distant measurements. The 
estimates therefore were biased by the most recent 
measurements.
4.3 VALIDATION OF BAYESIAN ESTIMATION
The Bayesian method of parameter estimation is 
initially dependent on the starting values, especially 
when few concentration measurements are available. The 
influence of the starting value of clearance was 
examined by altering the prior estimate by +/- 50%.
This was carried out in two patients and the results of 
this are shown graphically in Figures 4.2 (i) - (ii) .
The revised estimate on day 1 post-transplant was highly 
dependent on the prior estimate, due to lack of 
information from concentration measurements. By day 2 
it was seen that the prior estimate was relatively 
unimportant. More importantly, the same reduction in 
revised estimates of Cl/F was seen regardless of the
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Figure 4.2 Effect on revised estimates when changing the
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A second validation procedure was carried out to 
explore the influence of the number of concentration 
measurements in each dosing interval on the pattern of 
parameter estimates. It was thought .that the relatively 
early rapid accumulation of data might bias later 
parameter estimates. In the early (inpatient) stage of 
the study, two or three samples (including a trough 
sample) were collected daily. At later stages, only 
trough samples were collected and it was postulated that 
this might introduce bias. Using trough sample 
measurements only, the data were divided into 5 day 
units; 1-5, 6-10, 11-15, 16-20, 21-25, 26-30, 31-35, 36- 
40, 41-45, 46-50, 51-55, 56-60. Bayesian parameters 
were obtained using these data and compared to those 
obtained using all data sequentially. This study was 
carried out in the same two patients as above.
Estimates of Cl/F are shown graphically in Figure 4.3
(i)-(ii). It was seen that dividing the data into 5 day 
units and using trough samples only did not have an 
effect on the revised estimates and again the same 
reduction in clearance estimates was seen.
4.4 RESULTS
4.4.1 Relationship between dose and measured cyclosporin 
concentrations
Table 4.3 shows cyclosporin doses and trough
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Figure 4.3 Effect on revised estimates of Cl/F when 
using only trough concentrations from a 
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Table 4.3 Measured cyclosporin trough concentrations in 
eleven renal transplant patients 5 days 
post-operatively
Patient Dose
(mg/kg)
Dose
(mg)
Cone
(ug/1)
Conc/dose
(ug/l/mg)
1 15 1350 168 0.124
2 15 900 318 0.353
3 15 700 154 0.220
4 15 1150 239 0.208
5 15 850 183 0.215
6 15 750 112 0.149
7 15 1200 409 0.341
8 15 800 51 0.064
9 15 1100 372 0.338
LO 15 1200 73 0.061
LI 15 850 27 0.032
Mean 191 0.191
SD 129 0.117
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concentrations five days after transplant in each of the 
eleven patients. The mean cyclosporin concentration 
(SD) was 191 (129)ug/l. When the concentration was 
adjusted for the actual dose prescribed the mean value 
(SD) was 0.191 (0.117)ug/l/mg. Figure 4.4 shows 
graphically the lack of relationship between prescribed 
dose and resultant trough concentration of cyclosporin. 
This preliminary analysis demonstrates the poor 
relationship between dose and measured concentration, 
and the presence of wide inter-subject variability.
4.4.2 Prediction error analysis
For each set of Bayesian parameter estimates, later 
concentrations were predicted. The difference between 
the predicted and observed concentrations (prediction 
error) was calculated for each patient at various time 
points throughout the study. Concentration time data 
from the first five days were used to predict 
concentrations at days 10, 30 and 60. Ten days' data 
were used to predict concentrations at days 30 and 60 
and 3 0 days' data to predict to day 60 (Table 4.4).
This analysis was carried out for the one and two 
compartment models.
The prediction error (pe) for each patient at each 
of the above time points was calculated. The mean 
prediction error at each of the time points studied was 
calculated and was compared to zero using the one sample 
t-test (p<0.01). The results of this analysis are shown
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Table 4.4 Data used in calculation of prediction errors
Number of days data 
used in prediction
Concentrations predicted 
at days
5 10 , 30 60
10 30 60
30 60
Q
in Table 4.5 and in Figure 4.5. It can be seen that a 
statistically significant bias in prediction was 
observed at all time points except when 30 days data 
were used to predict concentrations at day 60.
4.4.3 Pharmacokinetic analysis
Measured cyclosporin concentrations at later time 
points were consistently higher than those predicted 
from Bayesian parameter estimates at early time points 
using either a one or a two compartment model. It was 
not surprising that the one compartment model produced 
poor predictions since cyclosporin is known to exhibit 
multi-compartment distribution characteristics 
(Ptachcinski et al, 1987a). In addition Kahan et al, 
(1986b) have reported that a two compartment version of 
a Bayesian program produced good revised estimates of 
pharmacokinetic parameters in renal transplant patients. 
Likewise, the Bayesian approach has been shown to be 
useful in bone marrow transplant patients assuming no 
changes occur in the pharmacokinetic parameters (Mentre 
et al, 1988). Estimated values of Cl/F are shown in 
Figure 4 .6 for the one and two compartment models at 
various time points throughout the study. Using the 
paired t test there was no significant difference 
between the estimates obtained from the two models.
The pharmacokinetic parameters associated with the 
two compartment model were studied in detail. The
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Table 4.5 Results of prediction error analysis
Time point One compartment Two compartment
mean (sd) mean (sd)
5(10) *57.1 (42.8) *51.1 (38.1)
5(30) *89.7 (71.6) *80.7 (59.1)
5(60) *78.3 (68.8) *71.5 (73.8)
10(30) *87.1 (51.6) *72.3 (43.9)
10(60) *76.0 (65.6) *65.5 (63.9)
30(60) 39.1 (74.1) 14.8 (78.4)
* denotes significant bias (p<0.01)
Prediction error = observed - predicted concentration
Fig. 4.5 Mean pe ( ± sd) at time points 
investigated
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absorption rate constant (ka), and the distribution and 
elimination rate constants O' and ft were not expected to 
change much from their prior estimates because the 
relatively high number of trough concentrations 
outweighed the information from other samples. Indeed, 
the evaluation of a Bayesian method by Kahan et al, 
(1986b) involved fixing these three parameters at 
constant values. Clearance (Cl) and volume of the 
central compartment (V1) did, however, change and 
Figures 4.7 and 4.8 show the mean estimates (sd) in 
eleven patients over the time of the study. The 
Bayesian program did, however, have a fixed value for 
bioavailability (F) set at 25%, and these graphs 
(Figures 4.7 and 4.8) actually represent changes in Cl/F 
and Vq/F respectively. The observed downward trend over 
time could therefore be due to a decrease in Cl and V^, 
an increase in F or a combination of all three.
The Bayesian estimates of Cl/F and V-^/F showed 
considerable inter-patient variability at any time 
point. The mean (SD) estimate of Cl/F on day 2 post­
transplant was 34.4 (21.6) 1/h which decreased to 15.7 
(4.2) 1/h by day 60. Similarly, V^/F on day 2 was 137 
(128)1 which reduced to 44 (13.5)1 on day 60.
4.4.4 Relationship between cyclosporin pharmacokinetics 
and other factors
The biochemical, haematological and clinical data 
collected throughout the study for each patient (Section
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Figure 4.7
Cl/F
(l/h)
Mean successive parameter values of Cl/F (±SD) 
in the first two months following renal 
transplantation
80
60 -
40 -
20 - m
— i
60
— i  r~
10 20
t  1 r
30
— i— 1— r~ 
40 50
Time post transplant (days)
Figure
V-j/F (1)
• 8 Mean successive parameter values of V^/F (±SD) 
in the first two months following renal 
transplantation
400 i
300 -
200 -
100 -
6050403020100
Time post transplant (days)
4.2.2) were examined in an attempt to correlate changes 
in these factors with cyclosporin pharmacokinetics 
following renal transplantation.
(i) Concurrent drug therapy
Many drugs have been reported to interact with 
cyclosporin as discussed in Chapter 1. All patients in 
the study were on a variety of drugs. From Table 4.6, 
it can be seen that few of the patients were on 
concurrent drug therapy which might affect the 
pharmacokinetics of cyclosporin (see Section 1.5). Low 
dose prednisolone, which has been reported to alter 
cyclosporin pharmacokinetics (Klintmalm and Sawe, 1984? 
Ost et al, 1985; Ptachcinski et al, 1987) was 
administered to all patients for the duration of the 
study. There were not enough cases of administration of 
other drugs which might potentially affect cyclosporin 
pharmacokinetics, to provide information on their 
effect.
(ii) Gastrointestinal dysfunction
It has been established that changes in 
gastrointestinal function will affect the absorption of 
cyclosporin (Atkinson et al, 1984). Vomiting and 
diarrhoea will clearly decrease the amount of 
cyclosporin absorbed. Vomiting, however had little 
effect on cyclosporin pharmacokinetics in this study 
because patients suffering from nausea had the dose 
withheld for several hours until the nausea had 
subsided. Acute diarrhoea occurred more often, but as
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with data on concurrent drug therapy, there were not 
enough cases of gastro-intestinal dysfunction in this 
study to provide conclusive information.
(iii) Biochemical and haematological measurements
It is possible that one or more of the biochemical 
and haematological factors measured could help to 
explain the variability in cyclosporin pharmacokinetics. 
This is investigated fully in Chapter 5.
4.5 DISCUSSION
Work described in this chapter has confirmed 
previous reports of wide pharmacokinetic variability of 
cyclosporin both within and between subjects (Kahan et 
al, 1983; Newburger and Kahan, 1983). It has also been 
demonstrated that the use of a standard one or two 
compartment model in a Bayesian parameter estimation 
system results in biased cyclosporin predictions in the 
early period following renal transplantation. After 
approximately one month (day 30), it is possible to make 
unbiased predictions although precision is still poor. 
The biased predictions appear to be the result of a 
change in the pharmacokinetics of cyclosporin within 
patients, as is shown by graphs of mean (SD) Cl/F and 
V ^ F  over time.
From these data, it is impossible to differentiate 
F from Cl and V-^ . An increase in the absorption of 
cyclosporin following renal transplantation has been
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observed (Kahan et al, 1983; Odlind et al, 1986; Wilms 
et al, 1988). Alternatively, the biased prediction 
errors may be a result of increased elimination half 
life with chronic cyclosporin therapy (Habucky et al, 
1988) or a combination of both improved absorption and 
decreased elimination (Newburger and Kahan, 1983).
The finding of a consistent change in cyclosporin 
pharmacokinetics over time in the early post-operative 
period is not unexpected. It is known that the dose of 
cyclosporin can be gradually reduced during the first 
year after transplantation (Tufveson et al, 1986). It 
is likely that changes in patients' physiology in the 
transition from renal failure to the normal state, may 
result in a time-related change in one or more of the 
pharmacokinetic parameters (Venkataramanan et al, 1989) .
Various theories have been proposed to explain the 
changes occurring. Absorption of cyclosporin may 
undergo a time-dependent change due to factors such as 
improved gastro-intestinal motility or improved bile 
flow as time progresses, or due to the presence of post­
operative ileus in the early stages. Olive oil (the 
vehicle for oral cyclosporin) can induce bile production 
(Guarini and Ferrari, 1985). Since the presence of bile 
is necessary for the absorption of cyclosporin (Ericzon 
et al, 1987) it is possible that chronic therapy with 
either cyclosporin or its vehicle, may improve 
cyclosporin absorption. Habucky et al (1988) were not
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able to show any difference in maximum concentration or 
in time to achieve peak blood concentration after 
chronic dosing with either olive oil or cyclosporin.
They did however, show an increase in elimination half 
life.
An alternative theory is based on cyclosporin's 
ability to inhibit iso-enzymes of the cytochrome P450 
system (Moochhala and Renton, 1986) leading to the 
hypothesis that during chronic therapy, cyclosporin 
inhibits its own metabolism, thus accounting for the 
decline in Cl/F.
Various groups have suggested that absorption of 
cyclosporin is dose-dependent, and as dose is decreased 
over time post-operatively, a higher proportion of the 
drug is absorbed (Ptachcinski et al, 1985a; Grevel, 
1988), possibly due to limited solubility of the drug in 
the gastro-intestinal tract (Reymond et al, 1988) . 
However, Wilms et al (1988) showed an increase in F at 
two time points using the same dose on each study day. 
Since all patients in this study were initially 
receiving high doses of cyclosporin which were gradually 
tapered, the possibility of a dose effect can not be 
excluded. This is examined in Chapter 5.
Variable binding of cyclosporin to lipoproteins and 
erythrocytes may explain the results of this chapter. 
Variability in the lipoprotein profile or haematocrit 
may contribute to inter-patient variability (Morse et 
al, 1988). In this study, such changes occur within
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patients and may contribute to the intra-patient 
variability. Changes in cholesterol concentration and 
in haematocrit will be studied in Chapter 5, along with 
other biochemical and haematological measurements.
In conclusion, changes in pharmacokinetics of 
cyclosporin in the early post-operative period have been 
observed. These changes prevent the use of a standard 
Bayesian program to accurately predict cyclosporin 
concentrations. Various theories have been proposed to 
explain the gradual change in pharmacokinetics, due 
either to an increase in F and/or a decrease in Cl and 
. Such changes must be taken into account in any 
dosage adjustment procedure. The mechanism responsible 
for the change is still open to speculation and the 
following chapter will attempt to model this change in 
pharmacokinetics.
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CHAPTER 5
FACTORS INFLUENCING CYCLOSPORIN PHARMACOKINETICS 
IN RENAL TRANSPLANT PATIENTS
5.1 INTRODUCTION
The results presented in Chapter 4 suggest that the 
cause of biased prediction errors for cyclosporin is a 
change in the pharmacokinetics of cyclosporin in the 
initial post transplant period. Such a change is not 
entirely unexpected since transplant patients undergo 
dramatic changes in their physiology in the transition 
from a disease•state (in this case the uraemic state) to 
a healthy state (Venkataramanan et al, 1989). It is 
possible that the gradual return to a "normal state" is 
responsible for the consistent change in 
pharmacokinetics. A change in pharmacokinetics over 
time following renal transplantation has been observed 
by several groups as discussed in Chapter 4. This 
chapter will discuss the background to the changing 
pharmacokinetics and will attempt to model this change.
5.2 BACKGROUND
It is possible that time can be used somewhat 
empirically to describe the changes in pharmacokinetics 
which occur within subjects after a renal transplant. 
However, in the transition from the uraemic state to the 
healthy state, various physiological changes may alter 
absorption, distribution and elimination of cyclosporin 
and a change in one or more biochemical or 
haematological factors may provide a useful index of the 
change in pharmacokinetics. These factors which may
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affect cyclosporin pharmacokinetics are discussed in 
Chapter 1. The question to be addressed in this chapter 
is whether time is the most important factor influencing 
the pharmacokinetics of cyclosporin post transplant, or 
whether there is a relationship between Cl/F and some 
other factor. Other variables measured during the 
course of this study will be investigated in an attempt 
to identify some of the variability in Cl/F in the early 
post-operative period.
5.3 TIME DEPENDENT PHARMACOKINETICS
5.3.1 Data Analysis
Examination of the individual patient graphs of 
Cl/F versus time suggested that an exponential decline 
in Cl/F might satisfactorily explain the relationship. 
This can also be seen from the graph of mean values of 
Cl/F versus time shown in Figure 4.7. On the basis of 
these graphs, the following three monoexponential models 
were fitted to the data:
Model 1 Cl/F = 6 i & ~  ^ 2t + $ 3 Equation 5.1
Model 2 Cl/F = ^ 1 (l-^2 + 0 2e~ Equation 5.2
Model 3 Cl/F = 6 ± ” $3 + ^3e” Equation 5.3
These models are shown in Figure 5.1. Model 1 assumed 
that Cl/F declined monoexponentially from an initial 
value of 6 1 + 6 3  at a rate specified by 6 2  until it 
reached a baseline value (6 3 )• Model 2 assumed that
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Figure 5.1 Monoexponential models investigated to 
describe the change in Cl/F over time
Cl/F at day 0
rate of change of Cl/F
final Cl/F
Time (days)
M odel! CI/F = e,e'02l + e3 
Model 2 Cl/F = 0, (I - 02 + 02 e’031 ) 
Model 3 Cl/F=e, -03 + 63 e 0,021
M O D E L 1 2 3
Initial Cl/F e, + e3 9, 0,
Rate of change 03 0)02
Final Cl/F 0, - e, e3 0,-03
there was a relationship between the initial value of 
Cl/F (0^ and the total extent of the change in Cl/F 
(0102) @2 was fractional change in Cl/F. Model 3
assumed a relationship between the starting value of 
Cl/F (0-^ ) and the rate of change in Cl/F (0^02) 
rate of change was proportional to the initial value.
These three models were investigated using the 
computer program NONMEM (described in Chapter 3) which 
allowed estimation of the parameters of each model and 
simultaneously estimated the variances associated with 
each parameter. All models were fitted using both 
additive and proportional errors to estimate the inter­
patient variability. The models were non-hierarchical 
and were compared by examination of the log-likelihood 
function (the objective function), and by examining the 
residual plots for abnormal trends. The variances 
associated with each parameter were also compared.
5.3.2 Results
The results for each model investigated are shown 
in Tables 5.1 (i) to (vi). The estimated parameters and 
the objective functions were almost identical, 
regardless of whether additive or proportional errors 
were used to estimate the inter-subject variability. 
Model 1 had the lowest objective function of the three 
(1255.5 compared with 1274.8 and 1297.2 for Models 2 and 
3 respectively). It can be seen that the variances
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Table 5.1 NONMEM parameter estimates obtained for three 
monoexponential models
(i) Model 1 Cl/F = e”^2t + Q (additive errors)
Parameter SE
01 36.2 22.0
1400 1350
CV(%) 103.4
ro
0.147 0.0194
^2 0.0228 0.0139
CV (%) 102.7
CO 14.3 1.29
^3 13.5 4.97
CV (%) 25.7
e 0.0305 0.0109
Obj 1255.5
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Table 5.1 NONMEM parameter estimates obtained for three
monoexponential models
(ii) Model 1 Cl/F = ^ e”^2t+ (proportional errors)
Parameter SE
*1 36.2 22.0
s 1.07 0.508
CV(%) 103.4
CM 0.147 0.0194
1.05 0.619
CV(%) 102.5
CO
14.3 1.29
CO 0.0663 0.0268
CV(%) 25.7
€ 0.0305 0.0109
Obj 1255.5
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Table 5.1 NONMEM parameter estimates obtained for three
monoexponential models
(iii) Model 2 Cl/F =0^(1 “ 0 2 + $2 e (additive errors)
parameter SE
0 1 40.6 7.49
* 1
1190 965
CV (%) 85.0
CM 0.756 0.0709
CM 0.0476 0.0101
CV (%) 28.9
6 z 0.139 0.0130
% 0.0238 0.0072
CV (%) 111.0
e 0.0562 0.0291
Obj 1274.8
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Table 5.1 NONMEM parameter estimates obtained for three
monoexponential models
(iv) Model 2 Cl/F = 0-j(1-02 + 02 e (proportional errors)
Parameter SE
01 40.6 8.82
0.726 0.548
CV(%) 85.2
02 0.756 0.0887
0.0832 0.0659
CV(%) 28.8
03 0.139 0.0421
^3 1.24 1.40
CV(%) 111.4
e 0.0562 0.0453
Obj 1274.8
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Table 5.1 NONMEM parameter estimates obtained for three
monoexponential models
(v) Model 3 Cl/F = - 0^ + Q ^ e ~ Q ' \ Q 2 \ (additive errors)
Parameter SE
*1 4 9 . 5 8 . 5 7
1 2 8 0 1 1 4 0
CV (%) 7 2 . 2
CM 0 . 0 0 2 7 3 0 . 0 0 0 5 3
^2 3 . 0 1 X 1 0 " 6 5 . 8 5 X 1 0 ” 7
CV (%) 6 3 . 3
#3 3 6 . 3 1 3 . 2
^3 1 2 0 0 1 1 2 0
CV (%) 9 5 . 4
e 0 . 0 3 2 7 0 . 0 2 2 1
Obj 1 2 9 7 . 2
Table 5.1 NONMEM parameter estimates obtained for three
monoexponential models
(vi) Model 3 Cl/F = 0-p $3 + (proportional errors)
Parameter SE
01 49.5 11.0
0.524 0.318
CV (%) 72.4
CM 0.00273 0.00125
02 0.400 0.435
CV (%) 63.2
^ 3
36.3 11.9
0 3 0.914 0.427
CV (%) 95.6
e 0.0327 0.0378
Obj 1297.2
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associated with each parameter are large, indicating 
wide inter-patient variability whichever model is used. 
There was little difference in the calculated 
coefficient of variation between the additive error 
models and the proportional error models. On the basis 
of the objective function, Model 1 was selected as the 
best model. Examination of plots of predicted Cl/F 
versus weighted residual for this model (Figure 5.2(i) 
and (ii)) showed little difference between the additive 
and proportional error models. These plots also 
suggested that it was not an inappropriate model.
Results for model 1 suggested that the initial 
value of Cl/F was around 501/h and declined gradually at 
a rate of 0.147day~1 to a final Cl/F of approximately 
141/h. From the rate of change, a half life of 4.7 days 
was calculated which suggested that, on average, the 
change in pharmacokinetics was complete within three 
weeks of transplantation. In order to maintain a 
constant steady state trough concentration during this 
time period, the dose would have to be gradually 
reduced. This is in agreement with earlier observations 
(Tufveson et al, 1986). In this study the dose was 
gradually reduced to about 40% of its original value.
Model 1 has subsequently been used in the modified 
version of the Bayesian program evaluated in Chapter 6.
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5.4 RELATIONSHIP BETWEEN BIOCHEMICAL. HAEMATOLOGICAL AND 
PATIENT DATA AND THE PHARMACOKINETICS OF CYCLOSPORIN
5.4.1 Introduction
Throughout the study described in Chapter 4 various 
demographic, haematological and biochemical measurements 
were made. The factors used in this analysis are shown 
in Table 5.2. There were not enough episodes of gastro­
intestinal dysfunction to include in the analysis and 
few drugs administered concurrently had been implicated 
in pharmacokinetic interactions with cyclosporin (see 
Section 4.4.4). The effect of concomitant drug therapy 
could not therefore be studied.
Along with changes in the pharmacokinetic 
parameters, marked changes occurred in the other 
variables measured. Mean values (+ sd) for each factor 
of interest are shown in Table 5.3 at various time 
points throughout the study period. From the data 
presented in Table 5.3 it can be seen that both 
pharmacokinetic and biochemical, haematological and 
demographic measurements showed gradual changes. Cl/F 
declined by 56% and V-^/F by 67%. Several variables 
increased? haematocrit 45%, haemoglobin 38%, albumin 
13%, and cholesterol 34%. Bilirubin showed no 
consistent change over the 60 days of the study. ALAT 
showed no obvious change other than on day 2 when the 
results may have been biased by two extremely high 
values. Creatinine concentrations decreased by an
Table 5.2 Biochemical, haematological and demographic 
variables measured continuously throughout study period
Variable (Abbreviation) Units
Haematocrit (Hct) (%)
Haemoglobin (Hb) (g/ 10 Oml)
Albumin (Alb) (g/i)
Cholesterol (Choi) (mmol/1)
Bilirubin (Bil) (umol/1)
Alanine amino transferase (ALAT) (I.U./l)
Creatinine (Crea) (umol/1)
Cyclosporin dose (Dose) (mg)
Patient weight (Wt) (kg)
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Table 5.3 Changes in pharmacokinetic parameters and
other variables (mean + SD) at various time 
points throughout the study
Time post transplant (days)
2 10 20 30 60
Cl/F 34.4 26.5 18.4 15.5 15.0
(21.6) (12.1) (5.7) (4.9) (4.3)
Va/F 136.5 96.9 74.4 54.0 44.5
(127.5) (66.4) (45.7) (18.5) (12.1)
Haematocrit 22.7 23.3 24.0 26.6 32.9
(3.7) (3.6) (4.5) (2.9) (2 .8)
Haemoglobin 7.9 8.1 8.1 9.1 10.9
(1.6) (1.3) (1.4) (0.9) (1.0)
Albumin 33.8 33.9 35.0 37.0 38.2
(3.8) (2.9) (4.4) (4.4) (4.4)
Cholesterol 5.0 5.4 6.5 6.7 6.7
(1.1) (0.9) (1.5) (1.8) (1 .6)
Bilirubin 7.5 9.6 8.4 9.8 6.7
(2.7) (6.5) (3.6) (7.1) (2.7)
ALAT *52.3 25.8 21.7 22.1 24.1
(68.7) (13.2) (8.5) (9.6) (14.6)
Creatinine 810 520 353 234 154
(399) (386) (307) (121) (46)
Dose 986 650 577 491 391
(219) (122) (147) (83) (63)
Weight 69 68 68 67 68
(15) (13) (13) (13) (14)
* Results may be biased by two extremely high 
values
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average of 81% which would be expected in a group of 
successful renal transplants. Patient weight did not 
appear to change over the course of the study. Figures
5.3 (i) to (x) show plots of Cl/F versus different 
variables (covariates) for a representative patient. 
These plots suggest considerable intra-patient 
variability in the variables measured.
The relationship between Cl/F and other variables 
measured during the course of this study has been 
investigated using two different techniques; (i) General 
Linear Interactive Modelling (GLIM) and (ii) non-linear 
Mixed Effects Modelling (NONMEM).
5.4.2 Multiple Linear Regression Analysis
(i) Background
The program GLIM (Baker et al, 1978) was used for 
the simultaneous analysis of the relationship between 
Cl/F and various other factors measured, including time 
post operatively. The background to this technique has 
previously been discussed in Chapter 3.
(ii) Data analysis
The data were initially analysed assuming that all 
relationships with Cl/F were linear since (with the 
exception of time), there was little evidence otherwise. 
A second analysis was carried out using the logarithm of 
Cl/F as the dependent variable since Cl/F has been shown 
to decline exponentially with time.
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Figure 5.3 Relationship between variables measured 
during study and Cl/F in one patient
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The simplest model was initially fitted which 
incorporated only a subject effect as follows
Cl/F = + € Equation 5.4
and the residual sum of squares calculated (RSSQ). This 
model described the data in terms of individual 
intercepts with slope of zero. Independent variables 
were then incorporated into the model one at a time 
using the method of forward stepping for multiple linear 
regression (Chapter 3). The most significant variable 
(ie the one that best explained the variability in Cl/F) 
was determined by calculating the F-to-enter statistic 
for each variable (Section 3.3)? the variable with the 
highest F-to-enter statistic was incorporated into the 
model as shown in Table 5.4 (i). At each stage in the 
forward stepping procedure, any variable with an F 
statistic which was not significant using F tables 
(p<0.001) was eliminated from the analysis. The level 
of significance of p<0.001 was used since multiple tests 
were carried out. Assuming no more than fifty tests 
were performed, this level of significance allowed 
confidence that any difference was significant at the 5% 
level. In the first step, dose was the variable with 
the largest F-to-enter statistic and it was incorporated 
as follows
Cl/F = + jS^dose +e Equation 5.5
This model described Cl/F in terms of individual
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Table 5.4 Results of multiple linear regression analysis 
using Cl/F as the dependent variable, where x 
is the covariate.
(i) Cl/F =  +
x SSQ F R2 Sig
(p<0.001)
Time 16830 28.6 61.6 Yes
Haematocrit 21480 16.3 51.0 Yes
Haemoglobin 28870 4.9 34.1 Yes
Albumin 20650 18.1 52.9 Yes
Cholesterol 24260 11.2 44.6 Yes
Bilirubin 32220 1.5 26.5 No
ALAT 23860 11.9 45.5 Yes
Creatinine 13260 44.0 69.7 Yes
Dose 12460 48.6 71.6 Yes
Weight 17160 27.5 60.8 Yes
Note: Accepting p<0.001 for individual tests since
multiple comparisons are being carried out (see text)
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intercepts (a^) and individual slopes (/3^ ) . The forward 
stepping procedure was continued, each time adding in 
the variable with the largest F-to-enter statistic 
(Tables 5.4 (ii) - (iv)). The analysis was stopped when 
addition of a further variable did not result in a 
significant F value. The addition of further variables 
into a model will always result in an improvement to the 
model. If the F-to-enter statistic is regarded as a 
test at every point then the overall confidence will be 
much less than 95%. A 'stopping rule' was therefore 
employed which used adjusted R2 to determine 
subjectively the point at which no further improvement 
in the model was seen. Adjusted R2 was calculated using 
Equation 3.13. A plot of adjusted R2 versus the number 
of parameters is shown in Figure 5.4(i). The choice of 
an appropriate "stopping point" is a highly subjective 
procedure and is usually taken to be the point where the 
graph levels off.
The procedure of forward stepping was repeated 
using the logarithm of Cl/F as the dependent variable. 
Multiple linear regression analysis was carried out in 
the same way as before and the results are summarised in 
Table 5.5.
(iii) Results
Using the method of forward stepping, a complex
model explaining almost 89% of the variability in CL/F 
. . . .  o ,was identified. Adjusted R^ values are shown m
Table 5.4 (ii)
ci/F = a$+ jfrjdose + y^x + e
X SSQ F R2 Sig
(p<0.001)
Time 8730 11.6 80.1 Yes
Weight 7216 19.8 83.5 Yes
Haematocrit 9952 6.9 77.3 Yes
Haemoglobin 10420 5.3 76.2 Yes
Creatinine 9838 7.3 77.5 Yes
Albumin 10560 4.9 76.9 Yes
ALAT 11090 3.4 74.7 Yes
Cholesterol 9786 7.5 77.7 Yes
123
Table 5.4 (iii)
Cl/F =Q'i+ jS^dose + Yjweight + + e
X SSQ F R2 Sig
(p<0.001)
Time 6216 4.2 85.8 Yes
Haematocrit 6775 1.7 84.5 No
Haemoglobin 6501 2.9 85.2 Yes
Creatinine 6077 4.9 86.1 Yes
Albumin 6211 4.3 85.8 Yes
ALAT 6710 2.0 84.7 No
Cholesterol 5936 5.7 86.5 Yes
Table 5.4 (iv)
Cl/F = a ^ +  jS^dose + YjWeight + cholesterol + +6
X SSQ F R2 Sig
(p<0 .001)
Time 5578 1.6 87.3 No
Haemoglobin 5673 0.6 87.1 No
Creatinine 4909 5.3 88.8 Yes
Albumin 5600 1.5 87.2 No
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Figure 5.4 Adjusted R2 versus number of parameters
used in multiple linear regression analysis
(i) dependent variable - Cl/F
R2(%)
100
80
60 -
40 -
20 -
15050 1000
Num ber of parameters
(ii) dependent variable - log Cl/F
Figure 5.4 (II)
R2 (% )
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15050 1000
Num ber of parameters
Appropriate "s lopping  time"
Table 5.5 Summary of results of multiple linear
regression analysis using log Cl/F as the 
dependent variable 
log ci/f = o a +  jSiX-L + YjX2 + <53X3 + £*ix4 + r/iXg +e
X "best" X F R2
X ± Time 40.1 70.5
X2 Creatinine 15.7 81.2
X3 ALAT 6.6 85.0
X4 Cholesterol 4.7 87.4
X5 Weight 3.8 89.1
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brackets. The most important single factor was dose 
which alone accounted for 72% (70%) of the variability: 
creatinine alone accounted for 70% (Table 5.4(i)). As 
indicated in Chapter 1, inclusion of either of these 
parameters may be clinically irrelevant. The analysis, 
however, was continued incorporating dose into the 
model. Using two covariates, ie dose plus a second 
variable, the best model contained dose and weight, and 
explained 84% (82%) of the variability (Table 5.4 (ii)). 
Addition of cholesterol explained 87% (85%) of the 
variability (Table 5.4 (iii)) and the further addition 
of creatinine concentration explained 89% (87%) (Table
5.4 (iv)). No further improvement was gained by adding 
other factors and the final model was:
Cl/F = a. ^  + P ^ d c s e  + ^weight + ^cholesterol + 
/f^creatinine +e
Examination of the graph of adjusted R2 versus the 
number of variables (Figure 5.4(1)) suggested that 
little improvement in the model was seen after inclusion 
of four variables.
Using log Cl/F as the dependent variable, time 
alone explained almost 71% (69%) of the variability. 
Further inclusion of creatinine concentration explained 
81% (79%), ALAT 85% (83), cholesterol 87% (85%) and 
patient weight 89% (86%). The best model was therefore 
log Cl/F = + ift^time + y ^creatinine + <5jALAT
cholesterol + rj ^  weight +e
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As before, examination of the graph of Adjusted R2 
versus number of variables (Figure 5.4 (ii)) suggested 
that little improvement in the model was seen after 
inclusion of four variables.
(iv) Discussion
Multiple linear regression analysis was carried out 
to identify sources of variability in Cl/F. Initial 
observation of individual patient plots of Cl/F against 
individual covariates suggested that all relationships 
were linear with the exception of time. Multiple linear 
regression analysis was therefore carried out on two 
data sets; firstly where all relationships with CL/F 
were assumed to be linear and secondly where all 
covariates were linearly related to log Cl/F.
However, although multiple linear regression may be 
a useful approach in describing variability in the data, 
several problems became apparent during this analysis.
(i) Inclusion of virtually any of the variables studied 
explained a considerable amount of the variability in 
Cl/F and it was impossible to determine whether 
variability in Cl/F was due to changes in one or more of 
the covariates or whether it was merely an association 
due to general recovery post operatively as discussed 
earlier ie, correlation between the variables was 
complicating the issue.
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(ii) Inclusion of further factors will improve the 
model. It was therefore necessary to use a "stopping 
rule" such as adjusted R2 which described the 
improvement in the model while taking into account the 
number of variables in the model. Selection of the 
appropriate "stopping point" was a subjective procedure 
and no statistical method of selecting the best value of 
R2 was available.
(iii) GLIM does not allow linear and non-linear 
functions to be fitted simultaneously. The analysis 
therefore had to be carried out twice; firstly using 
Cl/F and secondly using log Cl/F.
5.4.3 Non-Linear Mixed Effect Modelling (NONMEM) 
fi) Background
Further analysis of the data was carried out using 
the non-linear regression program NONMEM (Chapter 3), 
since this technique allowed simultaneous analysis of 
linear and non-linear relationships with Cl/F.
Multiple linear regression of Cl/F and log Cl/F 
suggested that there was- a relationship between 
cyclosporin Cl/F and one or more independent variables. 
Time appeared to be a strong influencing factor in the 
change in pharmacokinetics post-transplant. However, 
data analysis described in this chapter suggests that 
inclusion of a further variable in the model may be 
appropriate. This possibility was investigated further 
using NONMEM since this allowed linear and non-linear
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covariates to be fitted simultaneously.
(i i) Data analysis
To link with the multiple linear regression 
analysis described above, a simple linear regression 
model was investigated initially as shown in Equation 
5.6.
Cl/F = S 2 - Equation 5.6
where 0 ^ and 0 2 are parameters of the model and X is 
the covariate. The PRED file used is given in Appendix 
3. The results of this analysis are shown in Table 5.6. 
Intra-subject variability was explained to a greater or 
lesser extent by the covariates tested. Variables were 
compared by examining the objective function and also by 
comparison of the variances associated with 0 ^. The 
coefficient of variation (CV) associated with 0 ^  was 
lowest when albumin was used as variable and was 
approximately 15%. In some cases - in particular 
haemoglobin, ALAT and creatinine concentration - the CV 
associated with 0 ^  was very high (329%, 1203% and 825% 
respectively) suggesting that none of these variables 
was useful in explaining variability in Cl/F. The CV of 
0^ when time was incorporated was approximately 50% 
although the linear model used here may not be 
appropriate since it has previously been shown in this 
thesis that Cl/F declines exponentially with time.
In conclusion, using this model the factor which 
resulted in the lowest variance on 0 ^ was albumin,
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although it is known that cyclosporin is not highly 
bound to albumin (Lemaire and Tillement, 1982). The 
factor which had the lowest objective function was dose. 
However, as discussed in Chapter 4, the relationship 
between Cl/F and dose may be spurious. Time post- 
operatively appeared to be a powerful factor in 
describing the change in cyclosporin pharmacokinetics 
and its objective function of 1713 was the second lowest 
using this linear model. It was shown earlier in this 
chapter, however, that the relationship between Cl/F and 
time could be described by a monoexponential equation.
In order to fit the non-linear relationship with 
time and linear relationships with other covariates, 
further analysis was carried out using the most 
appropriate of the three monoexponential relationships 
between Cl/F and time studied earlier ie (Model 1).
Other covariates were added individually (Equation 5.7) 
Cl/F = + $3 + $4X Equation 5.7
where t was time post-operatively and X was the 
additional covariate. An example of the PRED file used 
for this model is given in Appendix 3.
The results of this analysis are shown in Table 5.7 
(i) to (ix). The variances associated with 0^, 0 2 and 
$ 2 were still large for each of the models, as shown by 
the values of rj and the calculated coefficient of 
variation for each parameter.
The models in this analysis were compared to the
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(i) Cl/F = ^  e " ^ 2* + #3 + $4 x patient weight
Parameter Estimate SE
01 24.2 69.5
^1 1240 739
CV(%) 145.5
02 0.134 0.0616
^2 0.0368 0.0211
CV(%) 143.2 •
#3 26.1 73.1
^3 39.6 198
CV(%) 24.1
-0.216 0.467
e 0.044 0.300
Obj 1225.5
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(ii) 01/F = $1 e $ 2t + 6 3  + Q ^ x  haematocrit
Parameter Estimate SE
*1 36.2 22.4
1400 1350
CV(%) 103.4
6 2 0.147 0.016
CM 0.0228 0.0138
CV(%) 102.7
0 z 14.3 3.65
CO
13.5 5.09
CV(%) 25.6
#4 7.04 x 10”3 0.117
e 0.030 0.011
Obj 1255.5
Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(iii) Cl/F = 0 . ,  e” ® 21 + 03 + 0  4 x haemoglobin
Parameter Estimate SE
35.7 22.2
1400 1290
CV(%) 104.8
$ 2 0.148 0.014
% 0.0236 0.015
CV(%) 103.7
CO 15.4 5.15
’ 3
14.0 5.49
CV(%) 24.3
04 -0.125 0.522
e 0.0306 0.0111
Obj 1254.9
134
Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(iv) Cl/F = ^  e" $2t+ x crea-tinine
Parameter Estimate SE
*1 39.5 11.7
V i 1050 875
CV(%) 82.0
e 2 0.126 0.0240
CM 0.0110 0.0817
CV(%) 83.2
CO 15.1 1.26
^ 3 14.4 5.46
CV(%) 25.1
0 4 -0.0051 3.8x10”
e 0.0287 0.0095
Obj 1244.2
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(v) Cl/F = 0 1e ’ ^ 2t+ 6 3  + 6  4 x  bilirubin
Parameter Estimate SE
30.6 20.9
*71 1390 1270
CV(%) 121.8
02 0.147 0.0185
1 2 0.0229 0.0140
CV(%) 102.9
03 14.4 1.32
^3 13.5 4.94
CV(%) 25.5
04 -0.0166 0.0841
e 0.0306 0.0107
Obj 1255.4
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(vi) Cl/F = 0 1 e" ^ 2t + 6 3 * 6 4  x albumin
Parameter Estimate SE
01 36.3 21.4
1390 1310
CV(%) 102.7
CM 0.146 0.019
^2 0.0222 0.0142
CV(%) 102.1
CO 12.3 4.86
^3 13.9 5.17
CV(%) 30.3
h 0.0511 0.133
e 0.0308 0.011
Obj 1254.7
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(vii) Cl/F = e"  ^21 + O 3  * O 4  x  ALAT
Parameter Estimate SE
e^ 37.5 20.6
1470 1340
CV(%) 102.2
CM 0.152 0.0136
v 2 0.0234 0.0140
CV(%) 100.6
03 15.0 1.43
*3 12.5 4.46
CV(%) 23.6
-0.0284 0.004
e 0.0298 0.0096
Obj 1245.5
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(viii) Cl/F = 0-j e ” ® + $ 3 + 0 4 x cholesterol
Parameter Estimate SE
0 1 33.1 21.7
1340 1220
CV(%) 110.3
CM 0.148 0.0178
ro 0.0263 0.0198
CV(%) 109.6
03 16.7 3 .30
CO 12.2 4.60
CV(%) 20.9
04 -0.374 0.564
e 0.031 0.011
Obj 1250.6
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Table 5.7 Results of NONMEM analysis incorporating
additional variables into the monoexponential 
model
(ix) Cl/F = ^ 1e " ^ 2t+ $3 + 04 x cyclosporin dose
Parameter Estimate SE
6 1 3 7 . 4 2 3 . 3
” 1 1 4 3 0 1 4 1 0
CV(%) 1 0 1 . 1
CM
Q
b
0 . 1 4 8 0 . 0 1 9 2
0 . 0 2 1 8 0 . 0 1 5 1
CV(%) 9 9 . 8
CO 1 5 . 1 1 . 6 9
% 1 3 . 8 2 . 9 9
CV(%) 2 4 . 6
- 0 . 0 0 2 1 . 4 4 X 1 0 '
e 0 . 0 3 1 1 0 . 0 1 8
Obj 1 2 5 4 . 7
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monoexponential model (Model 1) using the chi-squared 
test for the difference between the objective function 
obtained from fitting the full or reduced models, 
described in Chapter 3. The results of this are shown 
in Table 5.8. It can be seen from Table 5.8 that 
including either patient weight (p<0.001), creatinine 
concentration (p<0.001) or ALAT (p<0.005) significantly 
improved the model. Inclusion of patient weight in the 
model, however, resulted in increased coefficients of 
variation for each of the parameters, and increased the 
standard errors associated with the parameter estimates. 
ALAT appears to be useful since it significantly 
decreased the objective function, decreased the 
coefficients of variation and decreased the standard 
error associated with 0 i and 0 2 • T^e finding that serum 
creatinine concentration significantly improved the 
model was unexpected since renal function has previously 
been shown to have little effect on the pharmacokinetics 
of cyclosporin (Follath et al, 1983; Roberts et al,
1986).
The above analyses suggest that time is the single 
most important factor influencing the pharmacokinetics 
of cyclosporin post-transplant. However, it was shown 
in Chapter 4 that predictions made from day 30 post­
transplant are not biased. It can be assumed that the 
time dependent influence is not present after this time. 
Investigation of the relationship between Cl/F and other
Table 5.8 Hierarchical models tested and differences
in their objective functions
Model cf AObj P
1 Cl/F= 0i e -02t + fl3 - - -
2 ci/f= e ~ ^ 2t + d 3  + g . xwt 1 -30.0 <0.001
3 Cl/F= e ‘^ 2t + 0 3 + ^ 4 xHct 1 0.0 NS
4 Cl/F= #1 e 21 * 0 3 * $ xHb 1 -0.6 NS
5 Cl/F= e 2t + ^ 3 + ^ 4 xCrea 1 -11.3 <0.001
6 Cl/F= #1 e ^ 2t + ^ 3 + ^4 xBil 1 -0.1 NS
7 Cl/F= Oi e ~ ® 2x + 6 3 + Q 4 xAlb 1 -0.8 NS
8 Cl/F= e ~^2t + # 3 + 04 xAlat 1 -10.0 <0.005
9 Cl/F= e ~^2t + # 3 + 04 xChol 1 -4.9 NS
10 Cl/F= e 2t + ^ 3 + ^4 xDose 1 -0.8 NS
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variables can be carried out without the effect of time. 
The following function was fitted as before 
Cl/F = $2 ” #ix Equation 5.6
this time using data from days 30 to 60 only. The' 
results of this analysis are shown in Table 5.9. 
Comparison of the objective functions for each covariate 
suggested that bilirubin explained most of the 
variability associated with Cl/F, although inter-subject 
variability was large. It is of note that creatinine, 
which significantly improved the monoexponential model 
above, showed a very large degree of inter-subject 
variability in this analysis. No single covariate in 
this analysis appeared to usefully explain the 
pharmacokinetic variability of cyclosporin.
5.5 DISCUSSION
Work presented in this chapter has attempted to 
identify the variability in the pharmacokinetics of 
cyclosporin following renal transplantation. It appears 
that there Is a time related change in Cl/F in the first 
few weeks after a transplant. However, the influence of 
other factors cannot be ignored as trends in biochemical 
and haematological data may be related to the change in 
kinetics. Some of these factors may help to explain 
variability.
Inclusion of patient weight as a variable, 
significantly improved both models investigated by
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multiple linear regression and, the inclusion of weight as 
an additional variable in the monoexponential model 
resulted in a significant decrease in the objective 
function. Recent work in uraemic patients, however, 
suggests that the disposition of cyclosporin is not 
affected by obesity, despite its lipophilicity and 
pharmacokinetics of cyclosporin when normalised by ideal 
body weight are similar in obese and non-obese patients 
(Flechner et al, 1989). Despite improving the 
monoexponential model, creatinine concentration is 
unlikely to have any explanatory power for reasons 
discussed earlier. The relationship shown with Cl/F is 
probably spurious. Liver function might have 
been expected to influence Cl/F: ALAT explained 30% and
bilirubin only 4.9% of the variability when analysed by 
multiple linear regression. Including ALAT as a 
covariate in the monoexponential model resulted in a 
significant improvement in the model. The finding that 
ALAT may be useful in explaining variability in Cl/F in 
renal transplant patients is in agreement with earlier 
work (Reynolds et al, 1988).
Some studies have suggested a relative increase in 
bioavailability as the dose of cyclosporin is decreased: 
dose was progressively reduced in the present study 
(normal clinical practice to prevent an increase in 
trough concentrations). Data collected in this study do 
not allow any assumptions to be made as to the effect of 
decreasing dose on cyclosporin pharmacokinetics.
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Factors representing binding of cyclosporin either 
to red blood cells or to plasma proteins may be of 
interest, since cyclosporin is a low extraction drug 
(Venkataramanan et al, 1985a) and its clearance is 
therefore related to the degree of protein binding. A 
close relationship between lipoprotein levels and 
cyclosporin clearance in uraemic patients awaiting renal 
transplantation has been observed (Lithell et al, 1986; 
Lindberg et al, 1986) and it is postulated that this is 
due to a reduction in the fraction of cyclosporin 
unbound with increasing cholesterol concentration (Legg 
et al, 1988). In addition, clearance of cyclosporin in 
bone marrow transplant patients is higher than in other 
groups of transplant patients and this is probably due 
to lower haematocrit levels in the former group (Yee et 
al, 1988b). An increase in haematocrit within patients, 
as seen in this study, might therefore be expected to 
result in a decrease in cyclosporin clearance. Obvious 
trends in haematocrit, haemoglobin, albumin and 
cholesterol were observed. In spite of the finding that 
these variables were "useful" in the multiple linear 
regression analysis, they contributed nothing to the 
monoexponential model.
In conclusion, it would appear that the variability 
in cyclosporin pharmacokinetics which occurs in the 
first few weeks following renal transplantation can be 
largely explained by time. This somewhat empirical
146
model may in fact reflect changes in other factors since 
there were correlations between time and the other 
factors. There remains however, considerable 
variability between subjects and the following chapter 
will evaluate a modified Bayesian program which attempts 
to account for the changes in pharmacokinetics between 
patients while also taking account of a gradual time- 
dependent change in pharmacokinetics.
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CHAPTER 6
EVALUATION OP A BAYESIAN ESTIMATION PROGRAM INCORPORATING 
A TIME DEPENDENT CHANGE IN PHARMACOKINETICS FOR RENAL 
TRANSPLANT PATIENTS RECEIVING CYCLOSPORIN
6.1 INTRODUCTION
The results presented in Chapter 5 showed that the 
change in Cl/F of cyclosporin following renal 
transplantation was associated with changes in a number 
of other factors. It was impossible, however, to 
determine whether changes in other factors were 
associated with post operative recovery per se. or 
whether there was a strong relationship between these 
factors and cyclosporin pharmacokinetics. The analysis 
showed, however, that post-operative time was the most 
important factor in determining the value of Cl/F.
The variances associated with each of the 
parameters in the monoexponential model were large 
(Model l, Chapter 5), implying considerable variability 
between subjects. In this chapter, the incorporation of 
this model into a Bayesian parameter estimation program 
is discussed and its ability to predict cyclosporin 
concentrations in the early post-operative period is 
evaluated.
6.2 DATA COLLECTION
Twenty two consecutive renal transplant patients 
were recruited. Of these, the transplant was removed 
from one patient on day 5 due to surgical complications, 
one patient had his immunosuppressive therapy changed to 
azathioprine on day 12, and two patients were unable to 
complete the out-patient dosing and sampling
questionnaires (described later) necessary for accurate 
data collection. Eighteen patients completed the study, 
and data were collected from the time of hospital 
admission (ie immediately prior to transplant) to six 
weeks post-operatively. Details of these 18 patients 
are shown in Table 6.1.
Each patient received a single oral dose of 
cyclosporin immediately before transplantation (day 0) 
and all subsequent cyclosporin was administered orally 
once daily. Patients were asked to take their 
cyclosporin with the same diluent (milk, fruit juice 
etc) for the duration of the study. Blood samples were 
collected twice weekly on average from each patient: 
cyclosporin concentrations were measured in whole blood 
using a specific monoclonal radioimmunoassay (CYCLO-Trac 
SP RIA) described in Appendix 1 (Knepil and McPhillips, 
1989).
While in hospital, all cyclosporin dosing and 
sampling times were recorded accurately, either 
personally or by a member of the medical or nursing 
staff. Before discharge, patients were given a diary in 
which to record the time of daily cyclosporin 
administration. They also recorded the times of all 
blood samples collected at out-patient visits and all 
episodes of vomiting or diarrhoea were carefully 
recorded by nursing staff (while in hospital) or at 
home.
No drugs known to affect the pharmacokinetics of
1 /. Q
Table 6.1 Clinical details of patients completing the 
evaluation study.
Patient Age Sex Weight
(kg)
Diagnosis
1 49 M 79 Mesingial IgA 
nephropathy
2 47 M 83 Polycystic kidneys
3 29 M 72 Congenital bladder 
outflow obstruction
4 37 M 74 Chronic pyelonephritis
5 58 M 76 Pyelonephritis
6 62 M 71 Hypertensive nephrosclerosis
7 45 M 74 Neurogenic bladder
8 50 F 73 Bilateral staghorn calculi
9 50 F 50 Chronic pyelonephritis
10 19 F 40 Focal glomerulosclerosis
11 37 M 69 Diabetic nephropathy
12 36 M 89 Acromegally/nephrotic
syndrome
13 19 M 65 Medullary cystic disease
14 42 M 100 Chronic glomerulonephritis
15 38 M 78 Chronic glomerulonephritis
16 56 M 85 Glomerulonephritis
17 21 M 67 G1omerulonephritis
18 15 F 49 Reflux nephropathy
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cyclosporin were administered other than prednisolone 
which all patients received throughout the study.
6.3 BAYESIAN PARAMETER ESTIMATION
6.3.1 Background
All data were analysed using the four versions of a 
Bayesian program described below. The four models are 
summarised in Table 6.2 and the parameters estimated by 
each of the four models are shown in Table 6.3.
Model 1. - this uses a standard one compartment 
pharmacokinetic model with a weighting scheme which 
gives progressively less weight to more distant 
concentration measurements. Any change in clinical 
status is therefore accounted for by placing greater 
emphasis on the most recent concentration measurements. 
The weighting scheme used is
O  = 1.001T x 0.15 x Cj Equation 6.1
The weighting scheme used in this study is different 
from that used in the pharmacokinetic study in Chapter 
4, since in the present study the time between 
concentration measurements is greater.
Model 2 - this is a modified version of the one 
compartment model just described, where the change in 
Cl/F is also estimated. This model does not incorporate 
the weighting scheme shown in Equation 6.1 since all 
concentration measurements are allowed to contribute
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Table 6.2 Description of four versions of the Bayesian 
program investigated in evaluation study
Model Description
1 One compartment, constant Cl/F
2 One compartment, changing Cl/F
3 Two compartment, constant Cl/F
4 Two compartment, changing Cl/F
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Table 6.3 Pharmacokinetic parameters estimated by the 
four versions of the Bayesian program in 
the evaluation study
Model 1 * Model 2 Model 3 Model 4
ka ka ka ka
Cl/F Cl/F(0) Cl/F Cl/F(0)
V/F V/F V q/F v -l/f
delta Cl/F a delta Cl/F
kCl/F 0 kCl/F
O'
0
where CL/F(0) is Cl/F at day 0,
delta Cl/F is the total change in Cl/F,
kCl/F is the rate of change of CL/F.
153
equally to the estimation of the rate and extent of 
change in Cl/F. Cl/F at any time (Cl/F(t)) is modelled 
using the following equation with the parameters listed 
in Table 6.3 (Model 2).
Cl/F(t) = deltaCl/F x e“kcl/F x + (Cl/F(0)-deltaCl/F)
Equation 6.2 
Model 3. - similar to Model 1 except that it 
uses a two compartment pharmacokinetic model.
Model 4. - similar to Model 2 except that it uses a two 
compartment pharmacokinetic model.
6.3.2 Data Analysis
The data were analysed in two ways as follows;
(i) using only the first three concentrations to 
estimate Bayesian pharmacokinetic parameters 
f-iiV using all available data up to any time point to 
estimate parameters.
(i) Using the first three concentrations
Data collected in the first two weeks post 
transplant were used to estimate Bayesian parameters for 
each patient. According to the sampling schedule, two 
blood samples for cyclosporin measurement were to be 
collected from each patient per week although this was 
not always the case. Also, measurements made within 72 
hours of a period of gastro-intestinal dysfunction were
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omitted. In every patient however, at least three 
concentrations were available during the first two weeks 
and these were used to estimate Bayesian parameters and 
predict concentrations during subsequent weeks 3 and 4 
(Time A) and 5 and 6 (Time B), shown diagrammatically in 
Figure 6.1.
For each predicted concentration, a prediction 
error was calculated, ie,
prediction error = observed concentration-predicted 
concentration.
For all patients at each time period (ie Time A and 
Time B) the mean prediction errors and their standard 
deviations were calculated and these were compared 
between all four models to evaluate relative accuracy 
and precision.
(ii) Using all available data
A second method of data analysis involved using all 
data up to any particular time point to estimate 
Bayesian parameters and to predict the "next" 
concentration. In this way the first three 
concentrations were used to predict the fourth (during 
weeks 2-3), the first five concentrations were used to 
predict the sixth (weeks 3-4) and the first seven 
concentrations were used to predict the eighth (weeks 4- 
5). This is shown diagrammatically in Figure 6.2. The 
difference between this analysis and the previous 
analysis was that predictions were being made only 3 or
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Figure 6.1 Graphical representation of data analysis
using first three concentration measurements 
only
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Figure 6.2 Graphical representation of data
analysis using all previous data to
predict "next" concentration
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4 days ahead, an approach which is probably more 
clinically relevant.
6.4 RESULTS
(i) Using the first three concentrations
Figure 6.3 shows observed and predicted 
concentrations for the four models in one patient 
(Patient 2). The mean prediction error and standard 
deviation in each patient during each time period is 
shown in Table 6.4 (i) - (iv) and a summary of these 
results is shown in Table 6.5 (i).
Absolute mean prediction errors for each model were 
compared using Friedman non-parametric analysis of 
variance. The results of this analysis are shown in 
Table 6.5(ii): there was no significant difference in 
the mean prediction error between Models 1 and 3 (the 
one and two compartment versions of the standard 
Bayesian program) or between Models 2 and 4 (the one and 
two compartment versions of the modified Bayesian 
program) at either Time A or Time B. Models 1 and 2 
were, however significantly different from each other at 
both times as were models 3 and 4. Models 2 and 3 were 
significantly different. Finally, there was no 
difference between models 1 and 4 at Time A although 
they differed at Time B.
The standard deviations of the mean prediction 
errors were used to assess precision and Table 6.6 (i)
156
Figure 6.3 Observed and predicted concentrations 
in one patient (Patient 2) when using 
first three concentrations only
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Table 6.4 Mean prediction error (±sd) for each patient at 
Time A and Time B, when using first three 
concentrations to revise pharmacokinetic parameters 
(i) Model 1 (One compartment,constant Cl/F)
PATIENT
Mean
TIME A 
pe sd Mean
TIME
pe
B
sd
1 16.3 11.8 59.3 55.7
2 115.3 77.8 156.5 74.7
3 66.3 14.7 126.5 52.2
4 52.0 112.5 107.0 29.2
5 26.8 32.3 192.5 40.6
6 63.0 4.2 58.0 64.6
7 168.0 101.9 122.7 55.1
8 77.7 9.3 79.3 17.9
9 51.3 27.4 13.0 51.7
10 102.5 19.4 87.0 56.2
11 -5.0 20.7 22.3 73.5
12 35.0 19.0 35.5 24.9
13 91.3 34.3 141.3 23.8
14 16.8 45.2 120.5 45.0
15 73.1 35.5 55.9 25.1
16 98.0 176.5 197.7 67.5
17 207.3 26.6 154.3 86.7
18 -4.5 37.4 72.3 54.6
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Table 6.4 Mean prediction error (±sd) for each patient 
at Time A and Time B, when using first three 
concentrations to revise pharmacokinetic parameters 
(ii) Model 2 (One compartment,changing Cl/F)
PATIENT TIME A TIME B
Mean pe sd Mean pe sd
1 2.0 12.2 50.0 54.8
2 23.0 21.3 -20.8 61.6
3 -21.1 23.7 19.8 38.6
4 31.8 72.3 -18.3 38.9
5 1.8 12.9 156.0 42.2
6 -16.0 12.7 -8.3 62.3
7 148.5 103.4 109.7 63.1
8 38.3 4.7 28.3 17.2
9 9.3 42.1 12.5 46.6
10 90.0 21.4 70.5 55.8
11 -16.3 20.1 16.2 72.3
12 -10.3 24.1 -9.8 40.4
13 60.0 28.8 95.3 20.5
14 -15.3 89.5 -25.5 44.7
15 -28.0 38.5 -13.7 28.9
16 -37.3 125.3 52.7 60.5
17 89.5 51.3 -24.8 80.6
18
in•I 54.4 -20.8 60.0
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Table 6.4 Mean prediction error (±sd) for each patient 
at Time A and Time B, when using first three 
concentrations to revise pharmacokinetic parameters
(iii) Model 3 (Two compartment,constant Cl/F)
PATIENT TIME A TIME B
Mean pe sd Mean pe sd
1 51.7 12.5 89.0 58.0
2 161.0 69.3 185.3 80.1
3 85.8 13.7 138.0 51.9
4 85.3 112.3 137.8 30.7
5 55.8 20.2 206.3 38.5
6 100.0 7.1 91.0 63.5
7 189.0 107.2 141.3 59.3
8 78.0 3.0 80.2 17.3
9 58.8 25.8 18.7 51.2
10 75.8 18.1 69.3 54.7
11 -7.0 19.7 22.8 71.9
12 12.0 21.9 12.0 25.7
13 82.3 31.5 132.5 23.4
14 30.8 46.7 128.5 45.0
15 72.0 34.7 56.3 25.3
16 116.0 176.0 213.3 68.0
17 213.3 26.6 158.7 87.2
18 12.0 29.7 94.0 47.5
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Table 6.4 Mean prediction error (±sd) for each patient 
at Time A and Time B, when using first three 
concentrations to revise pharmacokinetic parameters
(iv) Model 4 (Two compartment,changing Cl/F)
PATIENT TIME A TIME B
Mean pe sd Mean pe sd
1 53.0 17.0 25.3 65.2
2 -104.3 9.3 -40.8 32.5
3 61.3 14.5 110.8 44.8
4 -51.3 71.0 -20.0 37.3
5 18.8 20.1 176.3 40.6
6 -24.5 30.4 -6.0 53.4
7 161.5 105.8 121.3 64.7
8 77.0 3.6 79.7 17.8
9 45.5 24.3 8.0 52.3
10 23.3 23.1 -20.8 54.9
11 -15.0 19.7 17.8 72.0
12 -13.7 25.6 -39.0 23.9
13 55.0 28.2 88.3 19.6
14 -39.0 50.7 19.5 45.2
15 9.3 47.4 11.4 27.8
16 85.7 172.1 195.3 65.6
17 122.0 24.3 52.5 77.3
18 -3.0 29.7 85.3 44.0
160
Table 6.5 Comparison of mean prediction errors for
models 1 - 4 at Times A and B.
(i) mean (sd)
Model Time A Time B
1 69.5 (56.1) 100.1 (55.4)
2 17.1 (51.4) 26.1 (53.1)
3 81.8 (58.9) 109.7 (61.1)
4 25.6 (64.7) 48.1 (70.5)
(ii) Friedman analysis of 
prediction errors.
variance of mean
Model comparisons Significant difference
(p<0.05)
Time A Time B
1 2 Yes Yes
1 3 No No
1 4 No Yes
2 3 Yes Yes
2 4 No No
3 4 Yes Yes
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Table 6.6 Comparison of standard deviations of mean
prediction errors for models 1 - 4 at
(i)
Times A and B. 
mean (sd)
Model Time A Time B
1 44.8 (44.8) 49.9 (19.8)
2 42.2 (34.5) 49.4 (17.1)
3 43.1 (45.4) 50.0 (20.2)
4 39.8 (40.9) 46.6 (18.0)
(ii) Friedman analysis of variance of standard 
deviations of mean prediction errors.
Model comparisons Significant difference 
(p<0.05)
Time A Time B
1 2 No No
1 3 No No
1 4 No No
2 3 No No
2 4 No No
3 4 No No
shows the mean (sd) of these. The models were compared 
using Friedman analysis of variance which showed that 
there was no significant difference in precision between 
any of the models (Table 6 . 6 ( H ) ) ,
(ii) Using all available data
Estimation of Bayesian parameters using all 
available data was carried out for each of the four 
models. However, Model 4, the most complex model was 
not successful when more than three concentrations were 
used in four of the eighteen patients (patients 3,7,16 
and 18). The reasons for this are not clear but it is 
likely that in these patients variability in 
concentration-time data was too great to allow 
estimation of the seven parameters required by model 4. 
For this reason the present analysis deals only with 
models 1, 2 and 3. Figure 6.4 shows predicted 
concentrations using all previous data for the same 
patient (Patient 2) as shown in Figure 6.3.
The prediction errors at each of the times shown in 
Figure 6.2 ie concentration 4, concentration 6, and 
concentration 8, were calculated for models 1 to 3 as 
shown in Table 6.7 (i) - (iii). Mean (sd) prediction 
errors are shown in Table 6.8 . From this table it can 
be seen that bias appears to be reduced at each time 
point (as shown by smaller mean prediction error) using 
model 2 compared to models 1 or 3.
Absolute prediction errors for the three models
Figure 6.4 Observed and predicted concentrations
in one patient (Patient 2) when using 
all previous data
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Table 6.7 Prediction errors for each patient when using
•
all previous data 
(i) Concentration
for Models 
4 (week 3)
1, 2 and 3.
PATIENT Model 1 Model 2 Model 3
1 9 -6 43
2 42 27 96
3 71 12 96
4 -1 72 -12
5 —45 -5 40
6 66 -7 105
7 153 130 181
8 67 40 75
9 58 44 66
10 116 99 83
11 18 6 15
12 54 15 36
13 67 50 64
14 77 24 94
15 • 55 -67 53
16 -43 -135 -24
17 175 144 181
18 -31 -81 -9
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Table 6.7 Prediction errors for each patient when using 
all previous data for Models 1, 2 and 3.
(ii) Concentration 6 (week 4)
PATIENT Model 1 Model 2 Model 3
1 39 40 55
2 150 54 189
3 28 H 48
4 61 167 242
5 233 28 68
6 63 63 49
7 56 -46 123
8 59 -3 63
9 10 6 17
10 34 26 62
11 -5 -16 — 9
12 -14 -36 -14
13 88 76 99
14 -16 -7 -8
15 -26 -16 34
16 307 300 315
17 218 39 225
18 133 126 141
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Table 6.7 Prediction errors for each patient when using 
all previous data for Models 1, 2 and 3.
(iii) Concentration 8 (week 5)
PATIENT Model 1 Model 2 Model 3
1 -30
i
I h» o 4
2 41 -150 72
3 72 39 84
4 178 115 162
5 106 149 190
6 12 0 59
7 -13 -73 31
8 40 -27 46
9 -65 -73 -58
10 57 37 84
11 8 4 5
12 44 39 41
13 74 44 102
14 106 94 109
15 57 41 59
16 241 12 265
17 38 41 226
18 -13 -51 36
1
Table 6.8 Mean (sd) prediction errors when using all
previous data to predict "next" concentration
Concentration Model 1 Model 2 Model 3
4 50.4 (60.5) 20.1 (69.7) 65.7 (57.2)
6 78.8 (94.3) 45.1 (83.5) 94.4 (94.1)
8 52.9 (73.3) 12.8 (71.8) 84.3 (81.8)
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were compared at each time point using the Friedman 
analysis of variance (results are shown in Table 6.9).
It can be seen that the absolute prediction error 
associated with concentration 4 was not significantly 
different between any of the three models although the 
mean prediction error is less for model 2 than for 
models 1 or 3 (Table 6.8). The absolute prediction 
error for the sixth concentration in each patient was 
not significantly different between the standard and 
modified versions of the one compartment program 
although model 3 was significantly poorer than either of 
the one compartment models. There was no significant 
difference in absolute prediction error between models 1 
and 2 or between models 1 and 3 when the eighth 
concentration was predicted from the first seven 
concentrations. Model 2 was significantly better than 
model 3.
6.5 DISCUSSION
The use of a Bayesian approach to estimate 
pharmacokinetic parameters has been studied in renal 
(Kahan et al, 1986b) and in bone marrow transplant 
patients (Mentre et al, 1988). Both studies assumed 
that the pharmacokinetics were essentially constant 
within patients throughout the study. The "standard11 
approach was examined in Chapter 4 of this thesis and 
was found to produce biased prediction errors
1 AS
Table 6.9 Comparison of prediction errors when all
previous data are used to predict 'next'
concentration.
(Friedman analysis of variance, p<0.05).
Concentration Comparisons Significant 
p<0.05
1 2 No
4 1 3 No
2 3 No
1 2 No
6 1 3 Yes
2 3 Yes
1 2 No
8 1 3 No
2 3 Yes
1 AQ
due to a time dependent change in Cl/F of cyclosporin in 
the early post transplant period (Chapter 5). The 
present chapter has evaluated the use of a modified 
Bayesian program which takes into account the time 
dependent change in Cl/F.
A problem in the data analysis in this Chapter was 
the combined influence of the number of concentration 
measurements and the time elapsed following 
transplantation. Mentre et al (1988) suggested the use 
of two concentration measurements taken at optimum times 
which vary depending on the weight of the patient. 
However in the modified program evaluated here, time 
post transplant was also important. In general, two 
samples were collected from each patient per week. On 
several occasions a sample was either not taken or a 
measurement was omitted due to gastro-intestinal 
dysfunction. In addition, since these were routinely 
collected samples, timing of sample collection was not 
identical between patients. To overcome these problems, 
three concentrations collected within the first two 
weeks post transplant were used to estimate parameters.
Models 2 and 4 produced more accurate prediction 
errors at both time periods than models 1 and 3 
respectively. It was of interest that although model 4 
(the most complex model) was significantly more accurate 
than model 1 (the simplest model) at time B, this was 
not the case at time A where there was no significant 
difference between the models. It is likely that this
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was due to poor parameter estimates in model 4 which had 
seven parameters compared to three parameters required 
by model 1.
Neither of the modified programs improved the 
predictive precision. Several factors could be 
responsible for this. Cyclosporin is formulated in an 
oily vehicle as lOOmg cyclosporin /ml (Cavanak and 
Sucker, 1986). In hospital this was measured in a 
syringe and transferred to a cup by the nursing staff.
It is possible that after discharge from hospital, 
patients were not able to accurately measure the dose of 
cyclosporin, although it was explained to them before 
going home. Although the drug was then mixed with fruit 
juice or milk and the cup rinsed, it was difficult to be 
sure that the total amount of drug measured out had been 
swallowed by the patient. It would be interesting to 
carry out a similar study in patients receiving 
cyclosporin in soft gelatin capsules. This dosage 
formulation would enable more accurate administration of 
cyclosporin and may improve precision of prediction 
errors.
All patients appeared to understand the importance 
of taking their cyclosporin regularly and all completed 
the diaries. Non-compliance was therefore excluded as a 
source of imprecision.
The times of food intake may have affected the 
extent of cyclosporin absorption. In hospital,
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cyclosporin was administered approximately one hour 
after the evening meal. Co-administration of 
cyclosporin with food may either decrease absorption 
(Keown et al, 1982) or may increase it (Ptachcinski et 
al, 1985c). Since timing of cyclosporin dosage in 
relation to meals was not recorded after discharge, it 
is possible that this was an added source of 
variability. However the effect of food can not be 
solely responsible for the poor precision, since up to 
two fold intra-individual variation in AUC has been seen 
in fasting, healthy volunteers (Lindholm et al, 1988c).
The second data analysis, where all previous data 
were used to predict the next concentration, was more 
clinically relevant. This comparison was carried out 
for models 1, 2 and 3 as discussed earlier. As before, 
the problem of number of samples in relation to time 
post transplant arose. The concentrations to be 
predicted were therefore within defined time periods 
using a specific number of concentration measurements.
In each case, model 2 resulted in a smaller mean 
prediction error suggesting that this model was less 
biased. Friedman analysis of variance of absolute 
prediction errors showed no significant differences 
between models 1 and 2 at any of the times. In some 
instances model 3 was significantly poorer than models 1 
and 2. This may be due either to model 3 being an 
inappropriate model, or to poor prior estimates of the 
parameters.
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The prior estimates used throughout this thesis 
were taken from the literature (for pharmacokinetic 
parameters) or from the results in Chapter 5 (for the 
time dependent parameters). These were the best 
estimates available.
In conclusion, the use of a modified program 
improved accuracy but not precision when predictions 
were made several weeks ahead. Although cyclosporin can 
be described by a two compartment model, this model 
showed no advantage. If predictions are to be made only 
a few days ahead, it was shown that the standard and 
modified one compartment versions of the program were 
not significantly different.
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CHAPTER 7
EFFECT OF DIVERSION OF BILE FLOW BEFORE AND AFTER CLAMPING 
OF THE BILIARY T-TUBE ON THE PHARMACOKINETICS OF 
CYCLOSPORIN IN LIVER TRANSPLANT PATIENTS
7.1 INTRODUCTION
The introduction of cyclosporin has been a major 
factor in improving the success rate of liver 
transplantation (Starzl, 1985). As with renal 
transplantation however, (Chapters 4 and 6), significant 
pharmacokinetic variability necessitates frequent 
monitoring of blood cyclosporin concentrations (Burckart 
et al, 1986a; Venkataramanan et al, 1985c).
Liver transplant patients usually have a biliary T- 
tube inserted into the common bile duct during surgery. 
This is to drain bile and prevent blockage of the gall 
bladder during the recovery period. However, as bile is 
necessary for the absorption of cyclosporin (Ericzon et 
al, 1987), external biliary drainage may lead to poor 
absorption. This is important clinically because 
increases in trough concentrations after clamping of the 
T-tube have been reported (Andrews et al, 1985), and a 
comparative bioavailability study has suggested that 
absorption improves following clamping (Mehta et al, 
1988). It is unlikely that enterohepatic recycling of 
cyclosporin is involved in increasing bioavailability 
following T-tube clamping since very little drug is 
excreted unchanged in the bile (Venkataramanan et al, 
1985b).
The aim of the work described in this chapter was 
to examine the oral and intravenous pharmacokinetics of 
cyclosporin before and after clamping of the T-tube,
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leading to estimates of bioavailability and clearance. 
Any pharmacokinetic differences before and after 
clamping will be discussed in relation to demographic 
data collected during the course of the study.
7.2 METHODS
7.2.1 Insertion of Biliary T-tube
During liver transplant surgery a T-tube is 
inserted into the bile duct of the recipient (Figure 
7.1). The function of the T-tube is to allow drainage 
of bile to an external route in order to minimise the 
chance of biliary complications or obstruction occurring 
due to oedema following surgery. The T-tube was 
inserted about three centimetres into the common bile 
duct and the emerging long limb secured to the gall 
bladder wall and the skin of the abdomen. The T-tube is 
allowed to drain externally (unclamped) or is clamped so 
that bile flows back to the gut. The tube is typically 
unclamped for between two and five weeks following 
surgery. After this the tube is clamped and if no 
complications arise it is completely removed after eight 
or twelve weeks (Caine, 1976).
7.2.2 Patients
Thirteen consecutive orthotopic liver transplant 
patients were recruited. All were receiving cyclosporin 
as their main immunosuppressant therapy. Two patients 
died between the unclamped and clamped phases: eleven
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Figure 7.1 Diagram showing insertion of biliary T-tube 
in liver transplant patients
LIVER
common bile duct
Ju
T -  tube
all bladder
distal common 
bile duct
pancreatic duct
From Caine, 1976.
patients completed the study. Clinical details of the 
patients studied are shown in Table 7.1.
7.2.3 Cyclosporin Therapy and Blood Sampling
Cyclosporin was administered after an overnight 
fast, either orally as a solution or infused 
intravenously in 100ml saline at a constant rate over a 
two hour period. For each patient, during both the 
unclamped and clamped phases, an oral and an intravenous 
study were carried out within 48 hours of each other.
The dose of cyclosporin was based on clinical 
requirements determined by evidence of toxicity or 
rejection. Oral doses of cyclosporin ranged from 4- 
14mg/kg orally and 1.5-3.5mg/kg intravenously. All 
doses, routes and times of administration were 
accurately recorded by hospital staff during both 
periods of the study.
Serial blood sampling was carried out following 
oral and intravenous dosing. Blood samples for 
measurement of cyclosporin concentrations were collected 
at 0, 0.5, 1, 2, 2.5, 3, 4, 6, 8 and 10 hours after the 
start of the intravenous infusion and at 0, 1, 2, 3, 4, 
6, 8, 10 and 12 hours after an oral dose. All blood 
samples were collected in EDTA tubes and frozen at -20°C 
until required for analysis by HPLC (Chapter 2).
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Table 7.1 Clinical details of liver transplant patients 
completing the study.
Patient ‘ Age Sex Diagnosis
1 48 M Primary hepatic malignancy
2 38 M Primary hepatic malignancy
3 35 M Primary sclerosing cholangitis
4 27 F Chronic active hepatitis
5 48 M Primary hepatic malignancy
6 39 F Primary biliary cirrhosis
7 54 F Primary biliary cirrhosis
8 38 M Primary hepatic malignancy
9 22 F Chronic active hepatitis
10 41 M Primary hepatic malignancy
11 21 F Acute hepatic failure
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7.2.4 Data Collection
At the start of the study the clinical details 
shown in Table 7.1 were recorded for each patient. 
Throughout the study, body weight, temperature and blood 
pressure were observed. In addition, the following 
biochemical and haematological measurements and clinical 
observations were made: serum creatinine concentration, 
bilirubin, alkaline phosphatase (Alp), haematocrit, 
haemoglobin, albumin concentration and periods of 
nausea, vomiting or diarrhoea. In addition, initiation 
or discontinuation of drugs known to affect 
pharmacokinetics of cyclosporin, or a change in dose of 
such a drug, was noted.
7.2.5 Data Analysis
The area under the concentration-time curve (AUCq) 
following either oral or intravenous administrations was 
calculated using the linear trapezoidal rule (Section 
3.2.4). Due to complex dosing schedules of cyclosporin 
required in the early stages after liver 
transplantation, it was not possible to assume that 
steady state conditions existed. AUC from time zero to 
infinity (AUCq) was therefore determined by estimating 
the terminal elimination rate constant (ft) from the 
linear portion of the log concentration versus time 
curve and using equation 7.1.
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conc(t) - conc(O)
AUCq = AUCq + ------ --  Equation 7.1
This assumed that the terminal elimination phase 
represented only elimination, and that distribution was 
complete. Unfortunately, only three concentration 
measurements were usually available to estimate the 
terminal elimination rate constant so this could only be 
an approximation. Bioavailability (F) was then 
calculated as follows
/ox AUCOoral dose^v
F (%) =   x   x 100 Equation 7.2
AUCqIv  doseoral
Clearance was estimated from intravenous data using 
the following equation
dose(iv)
Clearance (1/h) =   Equation 7.3
AOCo(iv)
Bioavailability and clearance values before and after 
clamping of the T-tube were compared using the Wilcoxon 
Ranked Pairs test.
7.3 RESULTS
At the times of the unclamped and clamped studies 
no patient had any gastro-intestinal dysfunction. 
Administration of other drugs did not differ between the 
two study periods. In addition no patient received any 
drug known to inhibit or induce hepatic enzymes except 
for low dose prednisone which was given to all patients
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during both study periods.
Concentration-time profiles following oral and 
intravenous dosing before and after clamping of the 
biliary T-tube are shown for a representative patient 
(patient 8) in Figure 7.2 (i) and (ii). Both 
intravenous profiles show high concentrations following 
the 2 hour infusion period. The oral profiles, however, 
obviously differ from each other. While the T-tube is 
unclamped (free bile drainage) the profile is relatively 
flat. After clamping noticeably higher concentrations 
are achieved, despite a reduction in the dose.
The oral and intravenous doses administered to each 
patient and the corresponding estimates of AUCq5 during 
the unclamped and clamped studies are shown in Tables
7.2 and 7.3 respectively. The dose normalised AUCq 
after oral dosing, and the bioavailability were higher 
in all patients except for patients 2 and 5. This will 
be discussed later in this chapter.
Bioavailability and clearance were calculated for 
each patient using the data in Tables 7.2 and 7.3. The 
results for this are summarised in Table 7.4. 
Bioavailability while the T-tube was unclamped ranged 
from 3.0% to 34.7% with a mean (sd) of 14.5 (11.5).
After clamping of the T-tube, bioavailability ranged 
from 5.3% to 54.5% and the mean (sd) had increased to 
24.0 (14.2). Using the Wilcoxon Ranked Pairs test this 
difference was not significant.
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Figure 7.2 Oral and intravenous concentration time 
profiles before and after clamping of 
T tube (patient 8)
(i) T tube unclamped
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Table 7.2 Dose of cyclosporin administered to each
patient and estimates of AUCq3 for oral and 
intravenous studies when T-tube is unclamped
Patient Oral Intravenous
dose
(mg)
AUC
(ug/l.h)
AUC/dose 
(1/1.h)
dose
(mg)
AUC
(ug/l.h)
AUC/dose
(1/l.h)
1 800 3202 0.004 200 6091 0.031
2 300 8018 0.027 75 5782 0.077
3 400 1783 0.004 100 3222 0.032
4 400 699 0.002 100 5846 0.058
5 400 4569 0.011 100 4393 0.044
6 350 3242 0.009 100 2824 0.028
7 400 658 0.002 100 3445 0.034
8 400 1344 0.003 100 5383 0.054
9 300 881 0.003 100 4465 0.045
10 300 954 0.003 100 6915 0.069
11 400 3098 0.008 120 6500 0.054
Mean 0.007 0.048
sd 0.007 0.016
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Table 7.3 Dose of cyclosporin administered to each
patient and estimates of AUC^ for oral and 
intravenous studies when the T-tube is clamped
Patient Oral Intravenous
dose AUC AUC/dose dose AUC AUC/dose 
(mg) (ug/l.h) (1/l.h) (mg) (ug/l.h) (1/l.h)
1 800 8190 0.010 200 8627 0.043
2 500 1073 0.002 100 4088 0.041
3 300 2542 0.008 100 4338 0.043
4 500 9538 0.019 150 7516 0.050
5 400 1360 0.003 100 4978 0.050
6 500 7370 0.015 85 2300 0.027
7 500 3202 0.006 100 3842 0.038
8 300 5108 0.017 100 8554 0.086
9 350 4638 0.013 150 5671 0.038
10 600 11178 0.019 165 17457 0.106
11 500 9204 0.018 100 6764 0.068
Mean 0.012 0.054
sd 0.006 0.024
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Table 7.4 Estimates of clearance and bioavailability 
before and after clamping of the T-tube
Patient UNCLAMPED CLAMPED
Cl(1/h) F (%) Cl(1/h) F (%)
1 32.8 13.1 23.2 23.7
2 13.0 34.7 24.5 5.3
3 31.0 13.8 23.1 19.5
4 17.1 3.0 20.0 38.1
5 22.8 26.0 20.1 6.8
6 35.4 32.8 37.0 54.5
7 29.0 4.8 26.0 16.7
8 18.6 6.2 11.7 19.9
9 22.4 6.6 26.5 35.1
10 14.5 4.6 9.5 17.6
11 18.5 14.3 14.8 27.2
Mean 23.2 14.5 21.5 24.0
(sd) (7.7) (11.5) (7.7) (14.3)
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Estimates of clearance ranged from 13.01/h to 
35.41/h with a mean (sd) of 23.21/h (7.7) during the 
unclamped study. During the clamped study, clearance 
ranged from 9.51/h to 37.01/h with a mean (sd) of 
21.51/h (7.7). This difference was compared using the 
Wilcoxon Ranked Pairs test and was not significant.
The demographic data collected during the course of 
the study were examined. The data are shown for the 
unclamped and clamped study in Table 7.5. Measurements 
made before and after clamping of the T-tube were 
compared using the Wilcoxon Ranked Pairs test (p<0.05) 
and the results shown in Table 7.6. There were no 
significant differences in patient weight, albumin, 
bilirubin, alkaline phosphatase or serum creatinine 
concentrations between the two study periods.
Haematocrit and haemoglobin both increased significantly 
from the time of the unclamped study to the clamped 
study (p<0.05).
7.4 DISCUSSION
After liver transplantation, most patients receive 
cyclosporin intravenously in order to overcome the 
effect of poor absorption of the drug. Low absorption 
of cyclosporin in these patients is thought to result 
from the external diversion of bile away from the gut by 
T-tube (Mehta et al, 1988). This is consistent with 
knowledge that the presence of bile salts in the gut are 
necessary for solubilisation and absorption of
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Table 7.5 Haematological, biochemical and patient data
collected when T-tube was unclamped and clamped
Patient uc/c Weight
kg
Hct
%
Hb
g/di
Alb
g/i
Bil
umol/1
Alp
IU/1
Crea
umol/!
1 U C 58 30.4 10.1 35 22 240 107
c 58 37.8 11.5 36 22 195 126
2 uc 76 32.4 10.8 22 581 603 210
c 69 36.9 11.8 32 390 1119 79
3 uc 62 35.0 11.4 28 238 425 73
c 57 40.7 11.8 39 116 991 77
4 uc 47 32.7 10.5 33 55 553 54
c 46 33.7 11.2 35 33 648 73
5 uc 70 32.9 11.0 35 93 300 90
c 64 36.7 11.8 29 572 2581 97
6 uc 49 30.0 10.9 44 71 644 72
c 52 38.1 11.6 40 20 158 72
7 uc 50 26.1 9.0 42 58 197 176
c 63 34.1 10.9 38 20 337 131
8 uc 57 38.9 13.4 39 78 363 80
c 60 42.3 13.1 39 39 380 61
9 uc 57 40.2 13.1 48 103 600 54
c 65 42.9 14.0 46 26 329 50
10 uc 60 39.1 13.1 30 278 374 92
c 58 45.8 16.0 39 46 135 78
11 uc 54 27.5 9.2 38 72 205 113
c 54 27.0 9.0 38 38 173 113
uc - unclamped , c - clamped, hct - haematocrit /
hb - haemoglobin, alb - albumin, bil - bilirubin,
alp - serum alkaline phosphatase, crea - serum creatinine
185
Table 7.6 Comparison of haematological, biochemical and 
patient data before and after clamping of the 
T- tube using Wilcoxon Ranked Pairs Test
Variable Significant p<0.05
Weight No
Haematocrit Yes
Haemoglobin Yes
Albumin No
Bilirubin No
Alkaline phosphatase No
Serum Creatinine No
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cyclosporin (Ericzon et al, 1987). Information on the 
effect of clamping the T-tube and allowing bile to flow 
into the gut is of clinical interest because it 
influences the point at which intravenous therapy can be 
replaced by oral therapy.
The effect of time post-operatively on the 
pharmacokinetics of cyclosporin may be of importance in 
liver transplant patients since such an effect has been 
observed in renal transplant patients both in this 
thesis (Chapters 4 and 5) and in previous work (Kahan et 
al, 1983). Either an increase in bioavailability or a 
decrease in clearance could cause the increase in trough 
cyclosporin concentrations in liver transplant patients 
after clamping of the T-tube reported by Andrews et al 
(1985). Due to the clinical design of this study, the 
unclamped study was carried out before the clamped study 
in all patients and it was therefore not possible to 
study the effect of time post-operatively. However it 
is interesting to note that the lowest bioavailability 
observed during the unclamped study (3.0% in patient 4) 
was at 10 days post transplant which was the earliest 
time studied. Similarly the largest increase in 
bioavailability between the two study days was 28.5% 
(patient 9), where the clamped study was carried out 162 
days after transplant. The effect of time post- 
operatively can not be ignored, as improving liver 
function and bile flow will result in improving
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absorption over time (Burckart et al, 1986c).
In 11 patients studied in this thesis, the apparent 
change in bioavailability was from 14.5% to 24.0% 
although this difference was not significant. Mean 
clearance decreased from 23.21/h to 21.51/h, but again 
the difference was not significant. However, it was 
noted that although bioavailability increased in nine 
patients and decreased in two, there was an important 
clinical difference between the two groups of patients. 
The two patients (Patients 2 and 5) in whom 
bioavailability decreased at the time of the clamped 
study were suffering from vanishing bile duct syndrome, 
a condition characterised by a rapid destruction and 
disappearance of the interlobular bile ducts, associated 
with chronic rejection and cholestasis. Bile flow into 
the gut is impaired in these patients (Uchida et al, 
1989). The fact that these two patients did not show 
increased bioavailability after clamping supports the 
theory that improved bile flow to the gut improves 
absorption of cyclosporin.
The increased bioavailability in the nine patients 
with functioning grafts at the time of the clamped study 
(unclamped mean bioavailability 11.0%, clamped mean 
bioavailability 28.0%) was probably due to increased 
bile flow to the gut following clamping. In these nine 
patients there was no significant change in clearance 
between the two study periods.
Of the nine patients, one received the same oral
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dose during both study periods, six received an 
increased dose and two received a decreased dose at the 
time of the clamped study. A dose dependent effect due 
to limited drug solubility in the gut (Reymond et al, 
1988) is therefore unlikely to be responsible for 
increased bioavailability.
Various biochemical and haematological parameters 
measured during both study periods were compared (Table 
7.6). The number of red blood cells (as measured by 
haematocrit) and their haemoglobin content increased 
significantly from the time of the unclamped study to 
the time of the clamped study. Any change in binding of 
cyclosporin may affect its disposition (as discussed in 
Chapter 5 for renal transplant patients). Cyclosporin 
is highly bound to erythrocytes, and the increase in 
haematocrit and haemoglobin may represent increased 
binding of the drug. Since cyclosporin is a drug with 
low to intermediate extraction (Venkataramanan et al, 
1985a), its clearance would be expected to be altered by 
changes in binding (Yee et al, 1988b). There was, 
however, no change in clearance as might have been 
expected if binding of the drug was altered (Kasiske et 
al, 1988).
Cyclosporin is almost completely metabolised in the 
liver and it is known that moderate hepatic dysfunction, 
as determined by elevated serum bilirubin concentration, 
delays clearance of the drug (Yee et al, 1984). No
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change in clearance at the two study periods was 
detected. It is of interest to note, however, that in 
the two patients with poor liver function at the time of 
the clamped study, patient 5 showed only a slight change 
in clearance and patient 2 actually showed a large 
increase in clearance between the two study periods.
The findings in this study must be compared to the 
results discussed earlier in renal transplant patients. 
Following renal transplant it is known that 
concentrations of cyclosporin increase (Kahan et al,
1983) and it has been postulated in Chapters 4 - 6  that 
this is a time dependent change in either clearance, 
bioavailability or a combination of both factors. The 
effect of time post transplant may well be a 
contributory factor and it is likely that improvements 
in patients' physiology during the recovery post- 
operatively may alter pharmacokinetics (Venkataramanan 
et al, 1989). The clinical aspects involved in the 
study required that the unclamped study was always 
carried out first. Because of this it was impossible to 
investigate time as a contributory factor in the change 
in pharmacokinetics and it cannot be ruled out.
In conclusion, no significant improvement in 
bioavailability of cyclosporin was observed following 
clamping of the T-tube in 11 consecutive liver transplant 
patients. However, two patients with 
acute rejection of the graft in whom bioavailability 
decreased, may have biased the data analysis.
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The results from this study, suggest that increased 
cyclosporin concentrations following clamping of the T- 
tube are not due to changes in clearance of the drug. 
Further work is required to fully establish the effect 
of T-tube clamping on the bioavailability of 
cyclosporin.
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CHAPTER 8
GENERAL DISCUSSION AND CONCLUSIONS
In this thesis, pharmacokinetic variability of 
cyclosporin has been investigated in renal and liver 
transplant patients. The variability has been studied 
both within and between patients, and of particular 
interest is the variability occurring in the first few 
weeks following transplantation. Wide pharmacokinetic 
variability has been observed in the early post­
operative period following either renal or hepatic 
transplantation (Kahan et al, 1983? Burckart et al, 
1986a). The aim of this thesis was to quantify 
pharmacokinetic variability in order to improve the 
control of cyclosporin dosage adjustment.
Previous work has shown that regular monitoring of 
trough blood concentrations of cyclosporin is useful in 
prevention of transplant rejection (associated with low 
concentrations) and prevention of toxicity (associated 
with high concentrations) (Kahan et al, 1984). Standard 
dosage adjustment procedures, however, require that the 
patient is at pharmacokinetic steady state? in the case 
of cyclosporin this means that the patient must have 
been receiving the same dose of drug for-at least three 
days.
A pharmacokinetic approach suggested by Kahan and 
Grevel (1988) proposes that cyclosporin dosage 
adjustments are based on individual pharmacokinetic 
parameter estimates. The disadvantage of such an 
approach is that it requires collection of many blood 
samples in each dosage interval from each patient.
1 Q 2
An alternative approach is to use Bayesian methods 
as discussed earlier (Kahan et al, 1986b; Mentre et al,
1988). In this thesis, it was shown that either a one 
or a two compartment version of a Bayesian program was 
unable to provide accurate predictions of cyclosporin 
concentrations in renal transplant patients in the first 
few weeks after transplantation. Concentrations were 
consistently under predicted. Examination of estimates 
of Cl/F and V-j/F showed that these pharmacokinetic 
parameters declined over time after surgery. This 
finding supported the frequent observation that 
immediately after renal transplantation, patients 
require high doses of cyclosporin and this dose can be 
gradually decreased (Tufveson et al, 1986). The 
estimates of Cl/F were investigated in detail; previous 
reports had suggested that elimination decreases over 
time (Habucky et al, 1988), that F increases (Kahan et 
al, 1983; Wilms et al, 1988), or that both 
bioavailability and elimination are altered (Newburger 
and Kahan, 1983).
Graphs of Cl/F in individual patients and a graph 
of mean Cl/F over time in eleven patients suggested an 
exponential decline over time. Three monoexponential 
models were therefore investigated which related Cl/F 
and time (Chapter 5). Time was found to adequately 
describe the change in Cl/F within patients although 
there was wide inter-patient variability.
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The possibility that some factor other than time 
was responsible for the change in pharmacokinetics was 
investigated. Other factors measured throughout the 
study (eg biochemical or haematological factors) showed 
upward or downward trends which may have contributed to 
the variability in Cl/F. The change in these other 
factors was probably due to the dramatic changes in 
physiology that these patients undergo following 
successful renal transplantation (Venkataramanan et al,
1989). These factors were investigated using multiple 
linear regression techniques (GLIM) and non-linear mixed 
effects modelling (NONMEM). However, it was impossible* 
to determine whether the trends in these other variables 
were responsible for the change in Cl/F or whether it 
was a spurious association. Time post transplant was 
the most powerful explanatory variable. Even if one of 
the other factors had proved more useful than time in 
explaining the change in Cl/F, the problem of predicting 
that factor in an individual patient would then have 
been a difficulty. However, further work to establish 
if there is a relationship between some biochemical or 
haematological variable and cyclosporin pharmacokinetics 
would be of great interest. Such work would require 
collection of data from a considerably larger number of 
patients.
The most appropriate monoexponential model 
investigated (Model 1, Chapter 5), was incorporated into 
a modified Bayesian program to allow a gradual change in
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Cl/F. This modified program estimated three parameters 
related to Cl/F? namely C1/F(0) which was the value of 
Cl/F extrapolated back to zero time, kCl/F which was the 
rate of change in Cl/F, and deltaCl/F which was the 
total change in Cl/F. Substituting individual estimates 
of these parameters into Equation 5.1 enabled estimation 
of Cl/F(t) ie Cl/F at time t. This modification to the 
program was carried out for both the one and two 
compartment versions of the standard program.
A further group of renal transplant patients was 
recruited for evaluation of this modification. Four 
versions of a Bayesian program were evaluated; these 
were standard versions using either a one or a two 
compartment pharmacokinetic model and one and two 
compartment versions which had been modified to take 
into account the change in Cl/F. The ability of each 
version to predict cyclosporin concentrations was 
investigated. Future concentrations were predicted as 
far as four weeks. Although predicting as far ahead as 
this was not representative of the clinical use of such 
a program, it did provide useful information about 
accuracy and precision. It was seen that the one and 
two compartment versions of the modified program 
significantly improved the accuracy of the predictions 
but did not improve precision. Further analysis of the 
data, predicting concentrations only a few days ahead of 
time showed no significant difference in prediction
195
errors between a modified and a standard version of the 
one compartment program. This was probably due to the 
fact that only a small change in Cl/F would have taken 
place in the few days between estimation of 
pharmacokinetic parameters and the predicted 
concentration. The poor precision seen in all models 
may not have allowed detection of a small improvement in 
accuracy. However since the analysis predicting several 
weeks ahead of time showed the modified version to 
predict more accurately, it appears that this is a more 
appropriate model for cyclosporin. Poor precision of 
the prediction errors was observed and may have been due 
to one or more factors. Although non-compliance was 
eliminated as a possible source of imprecision, some of 
the patients may have had difficulty after discharge in 
measuring the correct dose of cyclosporin to take. 
Possibly some patients did not mix the cyclosporin and 
diluent adequately and some of the drug may have 
remained on the wall of the cup. Further evaluation of 
Bayesian estimation would be of interest in patients 
taking the more recent formulation of cyclosporin in 
soft gelatin capsules since this would eliminate this 
source of variability. Another factor which may have 
contributed to the poor precision was the timing of the 
dose of cyclosporin in relation to meals. There is 
considerable controversy as to the effect of food on 
cyclosporin pharmacokinetics (see Section 1.3.1) and a 
possible effect can not be ruled out. From the data
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available it was not possible to differentiate changes 
in biochemical or haematological measurements from the 
effect of time. It is possible, however, that one or 
more of these factors may have contributed to the change 
in Cl/F. Possibly the inclusion of patient weight, 
serum creatinine concentration or ALAT in a future model 
may improve the precision. Further investigation of the 
relationship between cyclosporin pharmacokinetics and 
demographic variables is required.
A study was carried out in liver transplant 
patients with the aim of identifying changes in the 
pharmacokinetics of cyclosporin, in particular 
bioavailability, following clamping of the biliary T- 
tube. No significant difference in either 
bioavailability or clearance of cyclosporin was seen. 
However, two patients who had deteriorating liver 
function with severe cholestasis and vanishing bile duct 
syndrome at the time of the post clamped study may have 
complicated the results. Omitting these two patients on 
the basis of this diagnosis resulted in a significant 
increase in bioavailability. It is possible that 
improved liver function at the time of the clamped study 
or a time dependent change as seen in renal transplant 
patients is involved in improved absorption.
In conclusion, this thesis has examined 
pharmacokinetics of cyclosporin in renal and liver 
transplant patients and has quantified some of the
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variability observed. A modified version of a Bayesian 
program has been developed which takes into account some 
of the intra-individual variability in renal transplant 
patients. However, further work is required to improve 
the precision of the prediction errors. Development of 
a version of a Bayesian program suitable for use in 
liver transplant patients would be of future interest.
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APPENDICES
Appendix 1. Specific radioimmunoassay used to 
cyclosporin concentrations in Chapter 6.
measure
216
Cyclosporin concentrations in Chapter 6 were 
measured by a specific radioimmunoassay method (RIA) in 
the Department of Biochemistry at the Western Infirmary, 
Glasgow. The method uses a monoclonal antibody which is 
specific for cyclosporin (Quesinaux et al, 1987) and an 
iodine-125 labelled cyclosporin derivative as the ligand. 
Results obtained using this assay are comparable to 
results from HPLC methods similar to that used in this 
thesis (Schrann et al, 1987). The assay was supplied in 
kit form by the manufacturers (CYCLO-Trac SP RIA Whole 
Blood, Incstar Corporation). Analysis was carried out 
using the method recommended by the manufacturers in the 
insert supplied with the kit except in the preliminary 
extraction step where 100Oul of methanol were used 
instead of the recommended 400ul. Validation of the 
method was as follows.
Accuracy
Accuracy was assessed by spiking whole blood with 
three known concentrations of cyclosporin and assaying 
these samples in triplicate. Results of this are given 
in Table Al.l.
Precision
Between day precision was assessed by repeat 
analysis of quality assurance samples supplied by the 
manufacturers. Results of this are given in Table A1.2.
217
Specificity
Specificity of the antibody for cyclosporin has been 
extensively tested by the manufacturers and was not 
included in this validation.
Sensitivity
The lower limit of detection of the assay was 
assumed to be that of the lowest calibration standard 
which was 20ug/l.
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Table Al.l Assessment of accuracy of specific radio­
immunoassay
Spiked concentration % Accuracy
1000ug/l
500ug/l
250ug/l
Table A1.2 Assessment of between day precision of 
specific radio-immunoassay
QC no. n Mean concentration CV(%)
1 24 113.6ug/l
2 24 363.lug/1
9.9
6.4
90
94
92
219
Appendix 2 Method of Laplace Transformation used to solve 
differential equations in Chapter 3 (Gibaldi and Perrier, 
1975) .
220
GLOSSARY
D Dose
F Bioavailability
ka First order absorption rate
t Time after dose
X Amount
Cone Concentration
V Volume
Cl Clearance
k First order rate constant
Subscripts ?
1 Central compartment
2 Peripheral compartment
e Elimination
221
MODEL 1 One compartment model with first order
absorption
Differential equations
dG/dt = -kaG Eq 1
dX/dt = kaG - keX Eq 2
Equation 1 is solved as follows?
sL(G) - Go = -kaL(G) where Go=Dose (D) at t=0.
L(G) = D/(s + ka) Eq 3
Equation 2 is solved?
sL(X) - Xo = kaL(G) - keL(X) where Xo = 0 for
first dose
L(X)(s+ka) = kaL(G) Eq 4
kaL(G) kaD
(s+ka) (s+ka)(s+ke)
Take inverse Laplace Transforms of Equation 5
kaD -ket -kat X  ------- (e K e x - - e Kat) Eq 6
ka-ke 
kaD 
V(ka-ke)
Cone = X/V = ---------(e“ket - e"kat) Eq 7
9 9 9
MODEL 2 Two compartment model with first order absorption 
Differential equations
dX-^/dt = k^G + k21X2 kl2^1 ~ klO”^l 8
dX2/dt = k21^2 Eq 9
These differential equations can be solved by the method 
of Laplace Transformation as before to give
Cone = Ae*”0^  + Be“^  + Ce“ka^ Eq 10
where
B
F.D.ka(k21 -a) 
v x (/3-a) (ka-a)
F.D.ka(k21 - ft) 
v1 (a-/5)(ka -p)
F.D.ka(k21 - ka)
C  -----------------
v^a-k.,) (0 -ka)
and a  and p  are the hybrid rate constants which relate to 
k12' k21 anc* k10 w^ere
CC + P = k12 + k21 + k10
D D
Cl/F  ---------  V-j/F--------
A/a + B / p A + B
Appendix 3 Files used to run NONMEM
224
(a) Example of a NONMEM control file (Chapter 5).
(b) NONMEM PRED subroutines used in the analysis of Cl/F 
data (Chapter 5).
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(a) Example of NONMEM Control File
D A ; A A L I S O N , D A T A
UKES N O N M E M . T A B L E
*  -4- A- :f
P.ROB EX P MODEL CL REG ON T I M E
DATA 1 0 3 3 3 1 3  0
IT E M 1 3  0 0 1
LABL SUB.T T I M E CL NT
l a b l ALAT CHOL DOSE AGE
hOKM
\ 2r~ 3  » 0 5 P "7 = 8  7 2 r  • j  . U ? S' 5  = 1 , 3  F 3  , U , F 4 JJ ; h D « 1 ? F 5 , U , r  3  » 0 )
3  i Ru 2  1 1 1 1 1  0 . 1  0
r HTA -  0 .  0 2 1 5 , 0
l u NR - 1 . 0 - l . o
UPPE 1 .  0 9  0 .  0
D IA G 0 ,  0 1
D I A G 0 ,  0 2
ESTM 0 1 5 0  0 3  2  0 0 0 0
COVR i
"i ABL 1 l
TABL 3 1 0 2  0 3  0
SCAT 1 8
SCAT 16 3
SCAT 15  3
SCAT 14  3
SCAT I S  14
SCAT 15  14
SCAT 16  2
SCAT 1 5  2
SCAT 14 2
END OF L I S T I N G  OF F I L E  t G O N V 0 2 , A L I  SON (1  , *  - 1 )  . C0N5AL.B
t\i. :4: :j; :}. :t: *: :k >. :f: :f. :f. :}: *  :4: *  *  :f
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■(b) NONMEM PRED File for Model
Cl/F * e ^2t + 0^  (additive errors)
S U B R O U T INE PRED < I C A L L , N E W I N D r T H E T A , D A T R E C , I N D X S , F , G,  H;
L-
C
c
D I M E N S I O N  T H E T A < 3 ) , D A T R E C  < 1 3 ) ?H < 1 ) , 6 < 3 ) , I N D X S * ! )
DOUBLE P R E C I S I O N  T H E T A , F , G ?H , T , A , B , E A T , X A E , E X P W C H ,  XCOV  
T = D A T R E C ( 2 )
A = T H E T A ( 1 )
B = T H E T A ( 3 )
X A E = T H E T A ( 2 )
E A T = E X P W C H ( - X A E * T )
F = A * E A T +  B
S ( 1 ) = E A T
0 ( 2 )  = -  A *  T E  A T
G ( 3 > = 1
H l i ) = F
r e t u r n
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P W C H ( X X )
DOUBLE P R E C I S I O N  XX 
I F ( X X . L E . - 5 0 . )  X X = -  5  0 .
I F ( X X . Q E « 5 0 . >  X X = 5 0 .
E X P W C H = D E X P ( X X )
RETURN
END
END OF L I S T I N G  OF F I L E  : S O N V 0 2 . N O N M E M < 1 , * 1 > . P R E D 1
(b) NONMEM PRED File for Model
_ n
C l / F  * 0-] e ^ t  + (p r o p o r t io n a l  e r ro rs )
SUBROUT I  NE PR E D  < I  C A L L , NEW I N D , T H ET A  , D A T R E C , I N D X  S F  ? & > H )
D I M E N S I O N  T H E T A ( 3 ) , D A T R E C ( 1 3 ) , H < 1 > ?S * 3 >  , I N D X S ( i )
DOUBLE P R E C I S I O N  T H E T A ,  F ,  G ,  H ,  T ,  A ,  B ,  E A T ,  XA E ,  EXPWCH, XCOV 
T = D A T R E C ( 2 )
A = T H E T A ( 1 )
B = T H E T A ( 3 )
X A E = T H E T A ( 2 )
E A T =  EXF'WCH < - X A E :,:T )
F = A * E A T  + B
O' ( 1 )  = E A T * A
6  ( 2  > = -  A T E A T X  A E
S ( 3 ) = B
H < 1 ) =F
R ETURN
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P W C H <XX >
DOUBLE P R E C I S I O N  XX 
I F C X X . L E . - 5 0 .  ) XX = -  5 0 .
I F ( X X . G E . 5 0 . >  X X = 5 0 .
EXPWCH = D E X P ( X X )
RETURN
END
END OF L I S T I N G  OF F I L E  : G G N V G 2 . A L I S O N ( i  , *  , 1)  . PR E D1X
:j: :t: :f::{: :j::{: :f: :f: .f. :f: :f: :f: :f: :f: .f: :f::{: :f:}: .(
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(b) NONMEM PRED File for Model
Cl/F * ^ ( 1  - 0 2 + 02 e'  03 t )  (additive errors)
S U B R O U T I N E  P R E S ( I G A L L , N E W I N D , T H E T A , D A T R E C , I N D X S , F , 6  
C  W  *'■'
L-
D I M E N S I O N  T H E T A ( 3 )  , D A T R E C < 1 3 ) , H <  1 ) , 3 0 3 ) , I N D X S <1)  
DOUBLE P R E C I S I O N  T H E T A ,  F r G , H ,  T ,  A , P , C , E A T ,  X A E •, EXPWCH-  
T = D A T R E C < 2 >
A = T H E T A  <1)
B = T H E T A ( 2 )
X A E = T H E T A ( 3 )
■ E A T = E X P W C H ( - X A E * T )
F = A *  <1 ~ B + B * E A T )
G < 1 ) = F / A
G ( 2 ) = - A + A * E A T
G ( 3 ) = - A * E * T * E A T
H < 1)  = F
RETURN
END
D u U b L b  r R E U l b ' i U N  F U N U i  I O N  EXF'NCH \ XX )
DOUBLE P R E C I S I O N  xX 
I F  ( X X . L E .  - 5 0 .  > X X = - 5 0 .
I F ( X X . G E . 5 0 . )  X X = 5 0  - '
E X P W C H = D E X P ( X X )
R ET U R N
END
MD OF L I S T I N G  OF F I L E  : GONV02.ALISON < i  , *  , 1 > . P R E D 3
i: .1- :t :i: :4: :i: A: A. .}: ;} :4: A: ;f: -A. A. :f: A. A: :f: :f: :f: :f: :f: :f;
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(b) NONMEM PRED File for Model
C l / F  * 0 ^ (1  - 6 2 * 6 2  e (p r o p o r t io n a l  e r r o r s )
S U B R O U T I N E  PR ED < I  C A L L  ? NEW IN D. ,  T H E T A ,  D A TR E C ,  I N D X S ,  F ,  G, H)
C
D I M E N S I O N  T H E T A  ( 3 )  DATREC < 1 3 )  ? H 1 )  r S v 3 )  ? I N D X S  < 1 )
DOUBLE P R E C I S I O N  T H E T A , F , G r H , T :. A , B ; C r E A T , X A E , E X P W C H , X C O V  
T = D A T R E C < 2 )
A = T H E T A  <1)
B = T H E T A ( 2 )
X A E = T H E T A ( 3 )
E A T = E X P W C H <- X A E * T )
F = A :,: (1 - B  + B :-:EAT )
6 ( 1 ) = F
S ( 2 )  = ( - A + A * E A T }  :}:B
0 < 3 > = - A * B * T * E A T * X A E
H < 1 ) = F
RETURN
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P W C H ( X X )
DOUBLE P R E C I S I O N  XX 
I F < X X . L E . - 5 0 . )  X X = - 5  0 .
I F ( X X . G E . 5 0 . )  X X = 5 0 .
E X PWCH= DE X P ( X X )
RETURN
END
END OF L I S T I N G  OF F I L E  : G G N V 0 2 .  A L I S O N  < 1 ,  * ,  i  ) .  P R E D 3 X
:i: :{: .4: .4; :f: :f: : } : :f: *  i- :>• -r
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(b) NONMEM PRED File for Model
Cl/F * d-\ ' d 3 + d 3  e ‘ 010*2t (additive errors)
•S UBROUTIN E P R E D ( I C A L L , R E W I N D . T H E T A , D A T R E C , I N D X S , F ,  G ?H)
D l M h N S l U N  THb I A ( 3 )  , D m T R e C ( 13 )  , H ( 1 ) r 6  ( 3 )  , I N D X S  ( 1 )
DOUBLE P R E C I S I O N  T H E T A ,  F ,  G , H FT , A , B , f . _ E A T ,  XA E ,  EXPWCH, XCOV 
T = D A T R E C * 2 )
A = T H E T A ( 1 )
.9 = TH ET A  ( 3 )
X A E = T H E T A  ‘' 2 )
EAT=EXF'WCH ( - A * X A E * T >
F = A - B  + B :*-'EAT
G ( i >  = 1 - X A E * B * T * E A T
G < 2  i  = -  A *  B :{: T *  EA T
G ( 3 )  = - 1 + E A T
H ( i ) = F
RETURN
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P N C H ( X X )
DOUBLE P R E C I S I O N  XX 
I F ( X X , L E . - 5 0 . )  X X = - 5 0 ,
I F ( X X . G E . 5 0 . )  X X = 5 0 .
E x P W C H = D E X P ( X X )
RETURN
END
END OF L I S T I N G  OF F I L L  ; G O N V 0 2 . A L I  S O N ( 1 , * , 1 1 ..P R E D2
•j. :f. :4: :f: :f A: :}: :}: A: A: :f: A„ :f. •*: :}: .1: .f. A: A: :f: :f:
n 'x i
(b) NONMEM PRED File for Model
C|/f • 0.,- 03 * 03 e-M.2t (proportional errors)
END
:i.
S U B R O U T I N E  P R E D  < I  C A L L , N E W I N D  ., T H E T A ,  DATREC.- I N D X S ,  F , G , H >
I-’ 1 NEN b I  UN 1 H ET A  ( 3 )  D A FR'Eu ( i 3 )  , H ( i  ) , G ( 3 )  , I N D  X S (1 )
DOUBLE P R E C I S I O N  T H E T A , F ,  G., H., T., A ,  B., C , E A T , X A E ,  EXPWCH, XCOV 
T = D A T R E C <2)
A = T H E T A U )
B = T H E T A 1 3)
X A E = T H E T A ( 2 )
EAT=E XPWCH < - A ' i:X A E :*:T )
F = A - B + B * E A T
0 a ; = •. I  - X A £ * B * T * E A T )  *A
G ( 2 )  -  -  A B :f: T :f: E A T  *  X AE
gH'3 /  = ( - i + E A T )  * 8
H <1> =F
RETURN
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P W C H ( X X )
DOUBLE P R E C I S I O N  XX 
I F  < X X , L E .  - 5 0 ,  ) XX = - 5 0 .
I F ( X X , E E , 5 0 . /  X X = 5 0 .
E X P W C H = D E X P ( X X )
RETURN
END
■Jr L i b  i I N S  OF" F I L E  ; GONV'02,  A L I S O N  ( i  , , 1 )  , P RED2 X
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(b) NONMEM PRED File for Model
C|/F = e 2 - X
S U B R O U T I N E  PRED < I C A L L , N E W I N D , T H E T A , D A TR E C,  I N D X S , F  , G,  H)
D I M E N S I O N  T H E T A  ( 2 )  , D A TR E C  < 1 3 )  , H' ( 1 )  , G ( 1 )  , I N D X S  < 1 )
DOUBLE P R E C I S I O N  T H E T A ,  F ,  G ,  H ,  T ,  A ,  B ,  C,  EAT', X A E ,  EXPWCH, XCOV 
T = D A T R E C ( 4 )
A = T H E T A (1>
B = T H E T A ( 2 )
F  = B -  A *  T 
G ( 1 )  = -  T 
H ( 1 ) =F  
RETURN  
END
DOUBLE P R E C I S I O N  F U N C T I O N  E X P W C H ( X X )
DOUBLE P R E C I S I O N  XX 
I F  <X X . L E . - 5 0 . )  X X = -  5  0 ,
I F ( X X . G E . 5 0 . )  X X = 5 0  «
E X P W C H = D E X P ( X X )
RETURN
END
END OF L I S T INO OF F I L E  : G O N V 0 2 . A LIS O N ( 1 , * , 1 ) . PRED5WT
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(b) NONMEM PRED File for Model 
Cl/F ■ 0-, e“ ^2t + 63 + 04 x
S U B R O U T I N E  F R E D  <I C A L L ? N E W I N D T H E T A , D A T R E C ,  I N D X S , F , & ,
DC MENS I  ON T H E T A  <4 )  , DA TR EC  *112) ? H C i ;  ?GC3> ? I N D X S < i >  
DOUBLE P R E C I S I O N  THETA? F ? G ? h ? T ?  A , B? E A T ?XAE,EXPWCH,XC 
T = D A T R E C(2>
XCOV= D A T R E C ( 4 )
A = T H E T A C l )
B = T H E T A ( 3 )
C = T H E T A ( 4 ) * X C O V  
X A E = T H E T A  <2 )
E A T = E X P W C H <- X A E * T )
F = A + E A T + B + C
S C I ) = E A T
G ( 2 )  = - A :|:T * E A T
GC3> = 1
H C1 ) = F
RETURN
END
DOUBLE P R E C I S I O N  F U N C T I O N  EXF'WCHCXX)
DOUBLE P R E C I S I O N  XX 
i F C X X . L E . - 5 0 . )  X X = - 5 0 .
I F C X X . G E . 5 u / .  XX = 5 0 .
£XPWCH=DEXPCXX)
RETURN
END ‘
* OF !_ I  S T I N G  OF F I L E  : G 0 N V G 2 .  N I V E N  C1 ? * ,  1*) . PRED1WT
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